[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 445
6. Holpuch AS, Hummel GJ, Tong M, Seghi GA, Pei P, Ma P, Mumper RJ, Mallery SR: Nanoparticles for local drug delivery to the oral mucosa: proof of principle studies. Pharm Res; 2010 Jul;27(7):1224-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Nanoparticle uptake and compound retention evaluations employed monolayer-cultured human oral squamous cell carcinoma (OSCC) cell lines and normal human oral mucosal explants.
  • RESULTS: Functional uptake assays confirmed significantly greater internalization of nanoparticle-delivered fluorescent probe relative to free-fluorescent probe delivery, while concurrently demonstrating nanoparticle uptake rate differences among the OSCC cell lines and the phagocytic control human monocyte cell line.
  • Mucosal explants exhibited nanoparticle penetration and internalization in the spinous and basal epithelial layers (7/10 specimens), and also exhibited the presence of the phase-III efflux transporters multidrug resistance-associated protein 1 (MRP1) and breast cancer resistance protein (BCRP).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2006 May 4;25(19):2785-94 [16407847.001]
  • [Cites] Pharm Res. 2005 Nov;22(11):1821-8 [16132346.001]
  • [Cites] Nutr Cancer. 2006;54(1):58-68 [16800773.001]
  • [Cites] Drug Dev Ind Pharm. 2006 Sep;32(8):973-80 [16954110.001]
  • [Cites] AAPS PharmSciTech. 2006;7(4):91 [17285742.001]
  • [Cites] Eur J Pharm Biopharm. 2007 May;66(2):268-80 [17182234.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):2-3 [18172244.001]
  • [Cites] Oncol Rep. 2008 Feb;19(2):425-33 [18202791.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14(7):2095-101 [18381950.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2421-30 [18413833.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4945-57 [18559542.001]
  • [Cites] J Clin Periodontol. 2008 Nov;35(11):976-84 [18976394.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Jan;2(1):22-6 [19139014.001]
  • [Cites] Pharm Res. 2009 Apr;26(4):977-86 [19137418.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):3918-26 [19383919.001]
  • [Cites] Pharm Res. 2009 Aug;26(8):1995-2001 [19513818.001]
  • [Cites] Pharm Res. 2009 Aug;26(8):2027-36 [19533305.001]
  • [Cites] J Control Release. 2009 Nov 16;140(1):2-11 [19665039.001]
  • [Cites] Clin Cancer Res. 2009 Nov 1;15(21):6724-31 [19861457.001]
  • [Cites] Colloids Surf B Biointerfaces. 2010 Jan 1;75(1):1-18 [19782542.001]
  • [Cites] J Biomed Nanotechnol. 2009 Apr;5(2):151-61 [20055093.001]
  • [Cites] Toxicol Appl Pharmacol. 2010 Feb 1;242(3):326-32 [19909766.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 5;92(1):69-73 [10620636.001]
  • [Cites] J Oral Pathol Med. 2000 May;29(5):220-5 [10801039.001]
  • [Cites] Anticancer Res. 2001 May-Jun;21(3B):1713-22 [11497251.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6112-9 [11507061.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Sep 23;51(1-3):81-96 [11516781.001]
  • [Cites] Oral Oncol. 2001 Dec;37(8):652-9 [11590075.001]
  • [Cites] Pharm Res. 2002 Jul;19(7):947-53 [12180546.001]
  • [Cites] J Pharm Sci. 2002 Sep;91(9):2016-25 [12210048.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5451-6 [12359752.001]
  • [Cites] Pharm Res. 2002 Dec;19(12):1901-6 [12523672.001]
  • [Cites] Pharm Res. 2003 Feb;20(2):212-20 [12636159.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7537-52 [14576857.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4546-52 [14597742.001]
  • [Cites] Pharm Res. 2004 May;21(5):803-10 [15180338.001]
  • [Cites] J Control Release. 2004 Sep 14;99(1):53-62 [15342180.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Immunol Methods. 1987 Jul 16;101(1):119-25 [3112235.001]
  • [Cites] Oncology. 1992;49(2):77-81 [1574255.001]
  • [Cites] N Engl J Med. 1993 Jan 7;328(1):15-20 [8416267.001]
  • [Cites] Gut. 1995 Nov;37(5):598-602 [8549931.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3307-14 [8764126.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):14-8 [9892176.001]
  • [Cites] Oral Oncol. 1999 Jan;35(1):86-92 [10211315.001]
  • [Cites] Arch Oral Biol. 1999 Jun;44(6):519-23 [10401530.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Oct;125(10):1083-9 [10522499.001]
  • [Cites] J Dent Res. 2005 Apr;84(4):294-301 [15790732.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3109-14 [16707609.001]
  • (PMID = 20354767.001).
  • [ISSN] 1573-904X
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA129609; United States / NCI NIH HHS / CA / R01 CA095901; United States / NIDCR NIH HHS / DE / T32 DE14320; United States / NCI NIH HHS / CA / R01 CA115197; United States / NCI NIH HHS / CA / R21 CA132138; United States / NCI NIH HHS / CA / CA095901-03; United States / NCI NIH HHS / CA / R01 CA095901-03; United States / NCI NIH HHS / CA / R01 CA95901; United States / NCI NIH HHS / CA / R21 CA132138-01A2; United States / NCI NIH HHS / CA / CA132138-01A2; United States / NIDCR NIH HHS / DE / T32 DE014320
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoic acid; 0 / Antibiotics, Antineoplastic; 0 / Boron Compounds; 0 / Fluorescent Dyes; ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC2883929
  •  go-up   go-down


7. Lallemant B, Evrard A, Combescure C, Chapuis H, Chambon G, Raynal C, Reynaud C, Sabra O, Joubert D, Hollande F, Lallemant JG, Lumbroso S, Brouillet JP: Reference gene selection for head and neck squamous cell carcinoma gene expression studies. BMC Mol Biol; 2009;10:78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reference gene selection for head and neck squamous cell carcinoma gene expression studies.
  • We present the first study that defines the suitability of 12 reference genes commonly used in cancer studies (ACT, ALAS, B2M, GAPDH, HMBS, HPRT, KALPHA, RPS18, RPL27, RPS29, SHAD and TBP) for the normalization of quantitative expression data in the field of head and neck squamous cell carcinoma (HNSCC).
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Gene Expression


8. Dahlström LA, Ylitalo N, Sundström K, Palmgren J, Ploner A, Eloranta S, Sanjeevi CB, Andersson S, Rohan T, Dillner J, Adami HO, Sparén P: Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int J Cancer; 2010 Oct 15;127(8):1923-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human papillomaviruses (HPV) are established as a major cause of cervical carcinoma.
  • Such evidence is available for squamous cell carcinoma, but not for cervical adenocarcinoma.
  • In conclusion, infections with HPV 16 and 18 are detectable up to at least 14 years before diagnosis of cervical adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1301-4 [16265348.001]
  • [Cites] Int J Cancer. 2000 May 1;86(3):429-35 [10760834.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):303-15 [16507827.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1025-31 [16803480.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):885-91 [17131323.001]
  • [Cites] J Natl Cancer Inst. 2008 May 7;100(9):622-9 [18445828.001]
  • [Cites] J Clin Microbiol. 2009 Mar;47(3):541-6 [19144817.001]
  • [Cites] Int J Cancer. 2009 Aug 1;125(3):525-9 [19449379.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1055-62 [11021808.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6027-32 [11085523.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(2):246-50 [11166153.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):63-73 [12556961.001]
  • [Cites] J Pathol. 2003 Dec;201(4):535-43 [14648656.001]
  • [Cites] Biometrics. 1988 Jun;44(2):355-67 [3390504.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):498-505 [7640239.001]
  • [Cites] Anal Quant Cytol Histol. 1995 Aug;17(4):221-9 [8526946.001]
  • [Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62 [9049358.001]
  • [Cites] Cancer Causes Control. 1997 Sep;8(5):755-63 [9328198.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):536-45 [9466653.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):159-66 [10487628.001]
  • [Cites] Cancer Detect Prev. 2004;28(6):461-4 [15582270.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2191-9 [16172231.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):171-5 [16404371.001]
  • (PMID = 20473898.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093378-01A1; United States / NCI NIH HHS / CA / R01 CA093378-01A1; United States / NCI NIH HHS / CA / R01 CA111720-01; United States / NCI NIH HHS / CA / CA111720-02; United States / NCI NIH HHS / CA / CA111720-01; United States / NCI NIH HHS / CA / 1R01CA93378-01A1; United States / NCI NIH HHS / CA / R01CA111720-02; United States / NCI NIH HHS / CA / R01 CA111720-02; United States / NCI NIH HHS / CA / R01 CA093378; United States / NCI NIH HHS / CA / R01CA111720-01; United States / NCI NIH HHS / CA / 5R01CA111720-03; United States / NCI NIH HHS / CA / R01 CA111720-03; United States / NCI NIH HHS / CA / R01 CA111720; United States / NCI NIH HHS / CA / CA111720-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ NIHMS207185; NLM/ PMC2930102
  •  go-up   go-down


9. Sotlar K: [Human papillomavirus infection. Pathology and molecular pathology]. Pathologe; 2008 Nov;29 Suppl 2:153-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cervical cancer is the second most frequent female malignoma worldwide and accounts for about 500,000 cases every year.
  • Persistent infections with a group of 15 so-called high-risk human papillomaviruses (HR-HPV) are the cause of cervical carcinogenesis of squamous cell carcinomas and for most of the adenocarcinomas.
  • The resulting loss of cell cycle control sets the basis for additional, as yet only incompletely discovered, genetic and epigenetic changes, finally leading to invasive growth.
  • In addition to cervical cancer, HPV infections are responsible for the development of genital warts (condyloma) and a number of vaginal, vulvar, and anal intraepithelial neoplasias.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / pathology. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Child. Female. Humans. Middle Aged. Papillomaviridae / genetics. Papillomavirus Vaccines / administration & dosage. Young Adult


10. Glynne-Jones R, Meadows H, Wan S, Gollins S, Leslie M, Levine E, McDonald AC, Myint S, Samuel L, Sebag-Montefiore D, National Cancer Research Institute Anal Sub Group and Colorectal Clinical Oncology Group: EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys; 2008 Sep 1;72(1):119-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
  • PURPOSE: 5-Fluorouracil (5-FU) + mitomycin C (MMC)-based chemoradiotherapy is standard treatment for patients with epidermoid anal carcinoma.
  • This phase II trial aimed to determine the feasibility, toxicity, and efficacy of capecitabine, MMC and radiotherapy (RT) in anal cancer patients.
  • METHODS AND MATERIALS: Radiotherapy comprised the schedule of the UK Anal Cancer Trial (ACT) II trial (50.4 Gy in 28 fractions of 1.8 Gy).
  • CONCLUSIONS: Capecitabine with MMC and RT in with patients anal carcinoma is well tolerated, with minimal toxicity and acceptable compliance.
  • We recommend testing this schedule in future national Phase III studies in anal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18472366.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 50SG953SK6 / Mitomycin; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Maw MK, Fujimoto J, Tamaya T: Expression of the inhibitor of DNA-binding (ID)-1 protein as an angiogenic mediator in tumour advancement of uterine cervical cancers. Br J Cancer; 2008 Nov 18;99(10):1557-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Inhibitor of Differentiation Protein 1 / biosynthesis. Neovascularization, Pathologic / metabolism. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Cancer Res. 1985;43:175-203 [2581424.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12718-23 [14555767.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Nucleic Acids Res. 1994 Mar 11;22(5):749-55 [8139914.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6065-8 [7954447.001]
  • [Cites] Cell Growth Differ. 1995 Jul;6(7):837-43 [7547505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13543-8 [14578451.001]
  • [Cites] Cancer J. 2004 Jan-Feb;10(1):27-32 [15000492.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1198-203 [15026801.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):884-8 [8611421.001]
  • [Cites] Mol Cell Biol. 1997 Dec;17(12):7317-27 [9372963.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2371-81 [9528806.001]
  • [Cites] Mol Cell Biol. 1998 Aug;18(8):4577-88 [9671467.001]
  • [Cites] Trends Cell Biol. 1998 Feb;8(2):58-65 [9695810.001]
  • [Cites] EMBO J. 1999 Feb 15;18(4):968-76 [10022839.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1249-54 [10098767.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):827-33 [10360662.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3041-4 [10397240.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9637-41 [10449746.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):815-22 [10487839.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):933-8 [16189525.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):186-9 [16595146.001]
  • [Cites] Cancer Lett. 2006 Dec 8;244(2):203-10 [16469432.001]
  • [Cites] Arch Pathol Lab Med. 1985 Aug;109(8):716-21 [3893381.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):670-7 [10537105.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1332-40 [10728695.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3662-5 [10910083.001]
  • [Cites] Nature. 2000 Oct 5;407(6804):592-8 [11034201.001]
  • [Cites] J Cell Sci. 2000 Nov;113 ( Pt 22):3897-905 [11058077.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5929-33 [11085505.001]
  • [Cites] Nature. 2001 Feb 22;409(6823):1067-70 [11234019.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7812-6 [11427735.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5703-6 [11479201.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6008-11 [11507043.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2569-77 [11745191.001]
  • [Cites] Oncogene. 2002 Mar 14;21(12):1812-22 [11896613.001]
  • [Cites] J Urol. 2002 Jun;167(6):2598-602 [11992094.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):721-5 [12016143.001]
  • [Cites] Mol Carcinog. 2002 Sep;35(1):42-9 [12203366.001]
  • [Cites] Ann Oncol. 2002 Oct;13(10):1598-604 [12377648.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):473-83 [12498716.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):779-85 [12576450.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):677-82 [12640673.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4498-508 [12881706.001]
  • [Cites] J Pathol. 2003 Aug;200(5):561-7 [12898591.001]
  • [ErratumIn] Br J Cancer. 2009 Jul 21;101(2):377-8
  • (PMID = 19002177.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Modulating Agents; 0 / Biomarkers, Tumor; 0 / Inhibitor of Differentiation Protein 1; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2584935
  •  go-up   go-down


12. Gockel I, Kammerer P, Brieger J, Heinrich UR, Mann WJ, Bittinger F, Eckardt VF, Junginger T: Image cytometric DNA analysis of mucosal biopsies in patients with primary achalasia. World J Gastroenterol; 2006 May 21;12(19):3020-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To determine DNA aneuploidy in mucosal biopsies of achalasia patients for subsequent rapid diagnosis.
  • Samples from 15 patients with squamous cell carcinoma as well as specimens obtained exclusively 2 cm proximal to the tumor served as reference tests.
  • The comparison of biopsies from achalasia patients with peritumoral and carcinoma specimens revealed statistically significant differences regarding the aneuploid rate (diploid: P < 0.0001; tetraploid: P = 0.001), grading of malignancy according to Boecking (P < 0.0001) and the 5c- (P < 0.0001), 7c- (P < 0.0001), and 9c- (P = 0.0001) exceeding rate with progredient DNA alterations in the respective order.
  • [MeSH-minor] Adult. Aged. Biopsy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / genetics. Esophageal Neoplasms / pathology. Female. Genetic Testing. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Middle Aged. Mucous Membrane / chemistry. Mucous Membrane / pathology. Precancerous Conditions / diagnosis. Precancerous Conditions / genetics. Precancerous Conditions / pathology. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Achalasia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2003 Jul 15;144(2):148-55 [12850378.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1413-8 [11684958.001]
  • [Cites] Surg Gynecol Obstet. 1969 May;128(5):1081-95 [4888701.001]
  • [Cites] Surgery. 1969 Dec;66(6):969-75 [5402540.001]
  • [Cites] JAMA. 1971 Mar 8;215(10):1638-41 [5107684.001]
  • [Cites] Anal Quant Cytol. 1984 Mar;6(1):1-8 [6547281.001]
  • [Cites] Cancer. 1991 May 1;67(9):2290-4 [2013036.001]
  • [Cites] Hepatogastroenterology. 1991 Dec;38(6):514-6 [1778581.001]
  • [Cites] Cytometry. 1991;12(7):614-21 [1723676.001]
  • [Cites] Gut. 1992 Feb;33(2):155-8 [1541408.001]
  • [Cites] Chest. 1992 Oct;102(4):1013-6 [1395735.001]
  • [Cites] Gastroenterology. 1992 Dec;103(6):1732-8 [1451966.001]
  • [Cites] Cytometry. 1992;13(8):886-92 [1459005.001]
  • [Cites] Cytometry. 1993 Oct;14(7):793-804 [8243208.001]
  • [Cites] Am J Surg Pathol. 1994 Apr;18(4):327-37 [8141427.001]
  • [Cites] Gastroenterology. 1995 Feb;108(2):545-9 [7835597.001]
  • [Cites] Ann Thorac Surg. 1995 Jun;59(6):1604-9 [7771859.001]
  • [Cites] JAMA. 1995 Nov 1;274(17):1359-62 [7563560.001]
  • [Cites] Gastroenterology. 1996 Sep;111(3):648-54 [8780569.001]
  • [Cites] Anal Quant Cytol Histol. 1996 Oct;18(5):345-50 [8908305.001]
  • [Cites] Histochem Cell Biol. 1999 May;111(5):345-58 [10403113.001]
  • [Cites] Dig Surg. 1999;16(3):180-5 [10436364.001]
  • [Cites] Arch Biochem Biophys. 1951 Jun;32(1):42-54 [14847662.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1960 Nov 9;35:653-63 [13726467.001]
  • [Cites] Monatsh Veterinarmed. 1962 Jun 4-Jul 27;88:658-62 [13887328.001]
  • [Cites] Ann Surg. 1964 Sep;160:474-87 [14206851.001]
  • [Cites] Am J Surg Pathol. 2000 Aug;24(8):1153-8 [10935657.001]
  • [Cites] Histopathology. 1999 Nov;35(5):445-53 [10583560.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Apr;21(4):727-33 [16677160.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3717-22 [11268444.001]
  • [Cites] Hepatogastroenterology. 2001 Mar-Apr;48(38):408-12 [11379319.001]
  • [Cites] Dis Esophagus. 2000;13(2):110-6 [14601900.001]
  • (PMID = 16718781.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC4124375
  •  go-up   go-down


13. Nahas CS, Lin O, Weiser MR, Temple LK, Wong WD, Stier EA: Prevalence of perianal intraepithelial neoplasia in HIV-infected patients referred for high-resolution anoscopy. Dis Colon Rectum; 2006 Oct;49(10):1581-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients underwent anal canal and perianal high-resolution anoscopy in the office with biopsy of suspicious areas.
  • Office perianal biopsies diagnosed two patients with invasive squamous-cell carcinoma and nine with high-grade squamous intraepithelial lesion.
  • Seven of the nine patients with perianal high-grade squamous intraepithelial lesion on office biopsy were submitted to multiple biopsies under general anesthesia.
  • One of these seven had an occult perianal squamous-cell carcinoma.
  • CONCLUSIONS: Perianal disease was common in this group of HIV-infected patients; 11 patients (21 percent of total) were diagnosed with squamous-cell carcinoma or high-grade squamous intraepithelial lesion.
  • Our data suggest that anal canal neoplasia often is accompanied by perianal disease and illustrates the need for biopsy of any suspicious perianal lesions.
  • [MeSH-major] Anus Neoplasms / etiology. Carcinoma in Situ / etiology. Carcinoma, Squamous Cell / epidemiology. HIV Infections / complications. Proctoscopy / methods


1
Advertisement
4. Wang L, Xue L, Yan H, Li J, Lu Y: Effects of ROCK inhibitor, Y-27632, on adhesion and mobility in esophageal squamous cell cancer cells. Mol Biol Rep; 2010 Apr;37(4):1971-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of ROCK inhibitor, Y-27632, on adhesion and mobility in esophageal squamous cell cancer cells.
  • However, little is known the effect of ROCK on cell adhesion and mobility in esophageal squamous cell cancer (ESCC), one of the most diagnosed cancers in China.
  • All these findings indicate that ROCK signaling pathway plays an important role in cell adhesion and mobility, suggesting that it may be used as a potential target for therapy of ESCC.
  • [MeSH-major] Amides / pharmacology. Carcinoma, Squamous Cell / pathology. Cell Movement / drug effects. Esophageal Neoplasms / pathology. Protein Kinase Inhibitors / pharmacology. Pyridines / pharmacology. rho-Associated Kinases / antagonists & inhibitors
  • [MeSH-minor] Cell Adhesion / drug effects. Cell Line, Tumor. Humans

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatol Res. 2008 Aug;38(8):810-7 [18507693.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Jul;295(1):C38-49 [18463228.001]
  • [Cites] Exp Cell Res. 2008 Oct 15;314(17):3162-74 [18694745.001]
  • [Cites] Mol Cancer Res. 2008 Sep;6(9):1410-20 [18819929.001]
  • [Cites] World J Gastroenterol. 2008 May 21;14(19):3054-8 [18494058.001]
  • [Cites] J Craniomaxillofac Surg. 2007 Jan;35(1):1-9 [17296306.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5549-57 [18055804.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Oct;291(4):C668-77 [16641163.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 Jun;20(6):1190-200 [10340938.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3317-25 [12882776.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1056:405-12 [16387705.001]
  • [Cites] J Biol Chem. 2009 May 29;284(22):15147-57 [19293150.001]
  • [Cites] Int J Oncol. 2008 Sep;33(3):585-93 [18695890.001]
  • [Cites] Int J Cancer. 1996 Jun 21;69(3):225-35 [8682592.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Dec;327(3):777-88 [18791066.001]
  • [Cites] World J Gastroenterol. 2008 Oct 7;14(37):5665-73 [18837082.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2006 May;38(5):318-26 [16680372.001]
  • [Cites] Neoplasia. 2008 Dec;10(12):1444-58 [19048123.001]
  • [Cites] Jpn J Cancer Res. 2000 Aug;91(8):811-6 [10965022.001]
  • [Cites] J Cell Biol. 2008 Nov 17;183(4):697-710 [19015318.001]
  • [Cites] Cancer Lett. 2009 Nov 1;284(2):122-30 [19303207.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11305-10 [18685096.001]
  • [Cites] Cancer Lett. 2007 Aug 18;253(2):236-48 [17360108.001]
  • [Cites] Gut. 2009 Aug;58(8):1121-7 [19398441.001]
  • [Cites] Biol Pharm Bull. 2008 Sep;31(9):1802-5 [18758081.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1500-9 [16565385.001]
  • [Cites] Trends Cell Biol. 2005 Mar;15(3):138-45 [15752977.001]
  • [Cites] J Pineal Res. 2009 Jan;46(1):15-21 [18482340.001]
  • [Cites] Kobe J Med Sci. 2007;53(3):125-34 [17684444.001]
  • [Cites] Mol Cancer Res. 2005 Aug;3(8):425-33 [16123138.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Histopathology. 2008 Apr;52(5):560-8 [18312357.001]
  • [Cites] J Biol Chem. 2006 Oct 6;281(40):29614-24 [16882662.001]
  • [Cites] Lab Invest. 2007 Nov;87(11):1149-58 [17876296.001]
  • [Cites] Cancer Lett. 2005 Jan 31;218(1):69-79 [15639342.001]
  • (PMID = 19649725.001).
  • [ISSN] 1573-4978
  • [Journal-full-title] Molecular biology reports
  • [ISO-abbreviation] Mol. Biol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Amides; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 138381-45-0 / Y 27632; EC 2.7.11.1 / rho-Associated Kinases
  •  go-up   go-down


15. Kleiner-Hancock HE, Shi R, Remeika A, Robbins D, Prince M, Gill JN, Syed Z, Adegboyega P, Mathis JM, Clifford JL: Effects of ATRA combined with citrus and ginger-derived compounds in human SCC xenografts. BMC Cancer; 2010 Jul 26;10:394
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: NF-kappaB is a survival signaling transcription factor complex involved in the malignant phenotype of many cancers, including squamous cell carcinomas (SCC).

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 2000 Feb;91(2):148-55 [10761701.001]
  • [Cites] J Immunol. 2002 Feb 1;168(3):1441-6 [11801687.001]
  • [Cites] Carcinogenesis. 2001 Jan;22(1):73-82 [11159744.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):975-83 [11274625.001]
  • [Cites] Nucl Med Biol. 2002 Feb;29(2):263-73 [11823132.001]
  • [Cites] J Agric Food Chem. 2002 May 22;50(11):3193-6 [12009985.001]
  • [Cites] Annu Rev Nutr. 2002;22:347-81 [12055350.001]
  • [Cites] Dev Dyn. 2003 Feb;226(2):237-44 [12557202.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):768-80 [14570043.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):203-8 [15380510.001]
  • [Cites] J Biol Chem. 1974 Nov 25;249(22):7130-9 [4436300.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Methods Enzymol. 1981;77:398-405 [7329316.001]
  • [Cites] J Biol Chem. 1986 Jan 25;261(3):1372-8 [2418014.001]
  • [Cites] Cancer Res. 1987 Oct 1;47(19):5097-101 [3621194.001]
  • [Cites] Curr Opin Cell Biol. 1994 Dec;6(6):825-31 [7880529.001]
  • [Cites] Jpn J Cancer Res. 1996 Apr;87(4):349-56 [8641965.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1995;30(6):445-600 [8770536.001]
  • [Cites] Oncology. 1996 Sep-Oct;53(5):386-91 [8784473.001]
  • [Cites] Jpn J Cancer Res. 1997 May;88(5):443-52 [9247600.001]
  • [Cites] Jpn J Cancer Res. 1997 Sep;88(9):821-30 [9369929.001]
  • [Cites] Cancer Res. 1998 Nov 1;58(21):4832-9 [9809987.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):7383-92 [15905586.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):2936-42 [16395701.001]
  • [Cites] Biol Chem. 2006 Apr;387(4):387-92 [16606336.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] Biosci Biotechnol Biochem. 2006 Dec;70(12):3062-5 [17151446.001]
  • [Cites] Zhongguo Zhong Yao Za Zhi. 2006 Dec;31(24):2049-52 [17357553.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1303-13 [17301064.001]
  • [Cites] Genes Dev. 2007 Jun 1;21(11):1396-408 [17510282.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19589-94 [18048326.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Feb 1;366(1):219-25 [18060855.001]
  • [Cites] Free Radic Biol Med. 2008 Dec 15;45(12):1663-73 [18845239.001]
  • [Cites] Cancer Cell. 2009 Apr 7;15(4):283-93 [19345327.001]
  • [Cites] Toxicol Lett. 2009 Mar 28;185(3):180-6 [19150646.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3423-32 [19417020.001]
  • [Cites] Mol Cancer. 2009;8:27 [19432991.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Oct;2(10):903-11 [19789299.001]
  • [Cites] Nucl Med Commun. 2009 Dec;30(12):908-17 [19794320.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Aug;66(3):467-74 [19940992.001]
  • [Cites] Nutr Cancer. 2000;36(2):191-9 [10890030.001]
  • (PMID = 20659317.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1K22CA102005-01A2; United States / NCI NIH HHS / CA / 1R21CA116324
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzyl Alcohols; 0 / Coumarins; 0 / Lipopolysaccharides; 0 / NF-kappa B; 0 / Plant Extracts; 495-02-3 / aurapten; 52946-22-2 / 1'-acetoxychavicol acetate; 5688UTC01R / Tretinoin; EC 1.13.12.- / Luciferases
  • [Other-IDs] NLM/ PMC2916922
  •  go-up   go-down


16. Abramowitz L, Benabderrahmane D, Ravaud P, Walker F, Rioux C, Jestin C, Bouvet E, Soulé JC, Leport C, Duval X: Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors. AIDS; 2007 Jul 11;21(11):1457-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors.
  • OBJECTIVE: To assess the prevalence of and factors associated with squamous intraepithelial lesions and condyloma [human papillomavirus (HPV)-related lesions) in HIV-infected patients.
  • RESULTS: Of 473 patients examined, (200 homosexual men, 123 heterosexual men, 150 women), 108 (23%) had histologically confirmed anal HPV-related lesions (36, 15 and 11% of the respective populations), including 51 (47%) with only endoanal localization.
  • Among these 108 patients, histological dysplasia of grades I or II and grade III were noted in 59 and two patients, respectively, invasive endoanal cancer in one; three patients also had high-risk oncogenicity HPV without dysplasia.
  • Independent identified associated factors of HPV-related condyloma were the number of incidents of sexual intercourse per month [odds ratio (OR) 1.04; 95% confidence interval (CI) 1.01-1.06], CD4 cell count below 200 x 10 cells/l (OR 3.22; 95% CI 1.37-7.60), history of anal HPV lesion (OR 4.57; 95% CI 2.13-9.81), and receptive anal intercourse (OR 2.30; 95% CI 1.11-4.77).
  • The two latter factors remained associated with histological dysplasia (OR 2.82; 95% CI 1.38-5.76 for history of anal condyloma, and OR 4.29; 95% CI 2.18-8.44 for receptive anal intercourse).
  • [MeSH-major] Anus Diseases / virology. Anus Neoplasms / virology. Carcinoma in Situ / virology. Condylomata Acuminata / diagnosis. HIV Infections / virology. Sexual Behavior
  • [MeSH-minor] Adult. Anal Canal / pathology. Anal Canal / virology. Cross-Sectional Studies. Female. Heterosexuality. Homosexuality. Humans. In Situ Hybridization. Male. Middle Aged. Odds Ratio. Papilloma / diagnosis. Papilloma / pathology. Papilloma / virology. Prevalence. Risk


17. Goto H, Ikenaga M, Yasui M, Miyazaki M, Mishima H, Tsujie M, Miyamoto A, Hirao M, Fujitani K, Nakamori S, Yoshida K, Tsujinaka T: [A case of salvage treatment for local recurrence of squamous cell anal carcinoma after chemoradiation]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2659-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of salvage treatment for local recurrence of squamous cell anal carcinoma after chemoradiation].
  • A 76-year-old woman consulted her local physician because she experienced anal pain during defecation.
  • She was diagnosed with squamous cell anal carcinoma and underwent chemoradiation (59.4 Gy + UFT 500 mg/5 days/week).
  • She was followed up and 8 months later, she experienced anal erosion and pain.
  • Functional preservation employing concomitant chemoradiation has become the standard treatment for most case of squamous cell anal carcinoma, with APR backup being a salvage procedure.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Salvage Therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224671.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 1-UFT protocol
  •  go-up   go-down


18. Tramujas da Costa e Silva I, de Lima Ferreira LC, Santos Gimenez F, Gonçalves Guimarães RA, Botinelly Fujimoto L, Barbosa Cabral CR, Venturim Mozzer R, de Souza Atala L: High-resolution anoscopy in the diagnosis of anal cancer precursor lesions in renal graft recipients. Ann Surg Oncol; 2008 May;15(5):1470-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution anoscopy in the diagnosis of anal cancer precursor lesions in renal graft recipients.
  • BACKGROUND: Renal graft recipients are one of the population groups known to be at high risk of developing anal cancer.
  • This study investigated the presence of subclinical anal squamous intraepithelial lesions and the diagnostic ability of high-resolution anoscopy in detecting these lesions in renal graft recipients followed-up in Manaus.
  • METHODS: In a cross-sectional study, 50 renal graft recipients were interviewed and submitted to high-resolution anoscopy with biopsies of acetowhite lesions or of the anal transition zone mucosa when acetowhitening was absent.
  • Considering the histopathological reports of the examined anal specimens as the gold standard, the diagnostic validation and precision measures of high-resolution anoscopy were calculated as well as the prevalence of anal squamous intraepithelial lesions in the studied population.
  • RESULTS: In 42 renal graft recipients with satisfactory histopathological readings, prevalence of anal squamous intraepithelial lesions or condyloma acuminatum (ASIL-ACU) was 23.81%.
  • CONCLUSIONS: With a prevalence of 23.81% of subclinical ASIL-ACU lesions, the studied renal graft recipients had all these lesions detected by high-resolution anoscopy, notwithstanding most anal transition zone acetowhitened biopsied areas did not reveal histopathological aspects of anal cancer precursor lesions or condyloma acuminatum.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / diagnosis. Carcinoma in Situ / diagnosis. Carcinoma, Squamous Cell / diagnosis. Kidney Transplantation


19. Iagaru A, Kundu R, Jadvar H, Nagle D: Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma. Hell J Nucl Med; 2009 Jan-Apr;12(1):26-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma.
  • Anal squamous cell carcinoma (ASCC) is a rare cancer of the gastrointestinal tract, representing less than 5% of the digestive malignancies.
  • The cytological and/or histological confirmation of a suspected lesion should be followed by a complete imaging evaluation to determine the extent of disease.
  • Our results showed that PET demonstrated the primary lesion at initial evaluation in 7 of 8 anal cancers and showed FDG- avid lymph nodes in 4 patients.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19330178.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


20. Yang P, Sun Z, Chan D, Cartwright CA, Vijjeswarapu M, Ding J, Chen X, Newman RA: Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced hamster cheek pouch model. Carcinogenesis; 2008 Nov;29(11):2182-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we examined the effect of Zyflamend, a product containing 10 concentrated herbal extracts, on development of 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced inflammation and oral squamous cell carcinoma (SCC).
  • The effect of Zyflamend on inhibition of LTB(4) formation was further confirmed with in vitro cell-based assay.
  • Adding LTB(4) to RBL-1 cells, a rat leukemia cell line expressing high levels of 5-LOX and LTA(4) hydrolase, partially blocked antiproliferative effect of Zyflamend.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Cricetinae. Disease Models, Animal. Rats

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Dent Res. 1961 Jan-Feb;40:3-15 [13772812.001]
  • [Cites] Oral Oncol. 1999 Jan;35(1):112-9 [10211319.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):2089-96 [15756036.001]
  • [Cites] In Vivo. 2005 Jan-Feb;19(1):247-52 [15796182.001]
  • [Cites] Mol Cancer Ther. 2005 Jun;4(6):865-75 [15956244.001]
  • [Cites] Nutr Cancer. 2005;52(2):202-12 [16201851.001]
  • [Cites] J Oral Pathol Med. 2006 Feb;35(2):81-5 [16430737.001]
  • [Cites] Biol Chem. 2006 Apr;387(4):365-72 [16606333.001]
  • [Cites] Carcinogenesis. 2006 Sep;27(9):1902-8 [16632477.001]
  • [Cites] Am J Epidemiol. 2006 Sep 15;164(6):556-66 [16847039.001]
  • [Cites] Laryngoscope. 2006 Oct;116(10):1842-5 [17003715.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2006 Dec;75(6):385-95 [17011176.001]
  • [Cites] Cancer Biol Ther. 2007 Feb;6(2):228-36 [17218785.001]
  • [Cites] Nutr Cancer. 2007;57(1):78-87 [17516865.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Cell Biochem Suppl. 1993;17F:83-90 [8412211.001]
  • [Cites] Oral Oncol. 2000 Mar;36(2):221-4 [10745176.001]
  • [Cites] Anal Biochem. 2001 Oct 15;297(2):183-90 [11673886.001]
  • [Cites] Head Neck. 2002 Feb;24(2):165-80 [11891947.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1307-13 [12151348.001]
  • [Cites] Int J Oral Maxillofac Surg. 2002 Aug;31(4):419-22 [12361077.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):672-4 [12618872.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1885-97 [12738747.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2003 Aug-Sep;69(2-3):99-109 [12895592.001]
  • [Cites] Oral Dis. 2003 Sep;9(5):227-34 [14628889.001]
  • [Cites] Cancer Lett. 2004 Jan 20;203(2):127-37 [14732220.001]
  • [Cites] Oral Oncol. 2004 May;40(5):461-73 [15006617.001]
  • [Cites] Curr Cancer Drug Targets. 2004 May;4(3):267-83 [15134534.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] Br J Oral Maxillofac Surg. 1990 Jun;28(3):155-9 [1966928.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 2;85(11):862-74 [8492315.001]
  • [Cites] Free Radic Biol Med. 1995 Feb;18(2):185-94 [7744301.001]
  • [Cites] Mol Carcinog. 1996 Aug;16(4):197-202 [8784462.001]
  • [Cites] Oral Oncol. 2005 Mar;41(3):304-12 [15743693.001]
  • (PMID = 18687669.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA101235
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Carcinogens; 0 / Plant Extracts; 0 / Zyflamend; 1HGW4DR56D / Leukotriene B4; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  • [Other-IDs] NLM/ PMC3697064
  •  go-up   go-down


21. Kreuter A, Brockmeyer NH, Wieland U: [Anal intraepithelial neoplasia and anal carcinoma: an increasing problem in HIV patients]. Hautarzt; 2010 Jan;61(1):21-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal intraepithelial neoplasia and anal carcinoma: an increasing problem in HIV patients].
  • [Transliterated title] Anale intraepitheliale Neoplasie und Analkarzinom : Ein zunehmendes Problem bei Menschen mit HIV-Infektion.
  • Anal dysplasia is common in HIV patients, especially in HIV-positive men having sex with men (MSM).
  • High-grade anal dysplasia can progress to invasive anal cancer.
  • As in cervical carcinoma, there is a cause and effect relationship between anal cancer and human papillomavirus (HPV) infection, especially with high-risk types such as HPV16.
  • Several experts have recommended screening programs for anal cancer, including anal cytology along the lines of the Pap smear in women.
  • Clinical inspection, lesion biopsy, and treatment of anal dysplasia are performed under high-resolution anoscopy.
  • Anal cancer is divided into cancer of the anal margin and cancer of the anal canal.
  • Early cancer of the anal margin is excised akin to squamous cell cancer of the exposed skin, whereas cancer of the anal canal is treated by radiochemotherapy.
  • Physicians working in the field of HIV/AIDS should regularly screen their patients for the presence of anal dysplasia and anal cancer.
  • Basic diagnostic workup includes clinical inspection of the perianal area, digital rectal examination, and anal cytology.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / prevention & control. Carcinoma in Situ / virology. HIV Infections / complications. Precancerous Conditions / diagnosis. Precancerous Conditions / prevention & control

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):56-61 [18156992.001]
  • [Cites] J Am Acad Dermatol. 2005 Apr;52(4):603-8 [15793509.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] Br J Cancer. 1997;75(5):722-8 [9043031.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2078-83 [18273049.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Int J STD AIDS. 2008 Feb;19(2):118-20 [18334066.001]
  • [Cites] Br J Surg. 1994 Apr;81(4):500-8 [8205420.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):355-73 [15137962.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2120-9 [11966387.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 Nov;6(11):925-34 [18410393.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Curr Opin Infect Dis. 2009 Apr;22(2):109-14 [19276878.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):715-7 [16916390.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Int J Colorectal Dis. 2002 Jul;17(4):203-15 [12073068.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2550-7 [18427149.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Curr Opin Oncol. 2009 Sep;21(5):433-8 [19587592.001]
  • (PMID = 19967333.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Botelho M, Oliveira P, Gomes J, Gartner F, Lopes C, da Costa JM, Machado JC: Tumourigenic effect of Schistosoma haematobium total antigen in mammalian cells. Int J Exp Pathol; 2009 Aug;90(4):448-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Schistosoma haematobium is endemic in several regions of Africa and has been shown to be associated with predominantly squamous cell bladder carcinoma.
  • The mechanisms underlying the association between S. haematobium and bladder squamous cell carcinoma is largely unknown.
  • All the reports so far, demonstrate exclusively an epidemiological evidence linking S. haematobium infection with squamous cell bladder carcinoma.
  • [MeSH-major] Antigens, Helminth / pharmacology. Carcinoma, Squamous Cell / microbiology. Schistosoma haematobium / pathogenicity. Schistosomiasis haematobia / complications. Urinary Bladder Neoplasms / microbiology
  • [MeSH-minor] Animals. Antigens, Nuclear / analysis. CHO Cells. Carcinogenicity Tests. Cell Proliferation. Cricetinae. Cricetulus. Immunohistochemistry. Male. Mice. Mice, Nude. Models, Animal. Random Allocation. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Parasitol. 2001 Apr;17(4):172-5 [11282506.001]
  • [Cites] Urol Int. 2008;80(1):90-7 [18204241.001]
  • [Cites] J Clin Invest. 2003 Oct;112(7):1116-24 [14523048.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1268-74 [15154012.001]
  • [Cites] Infect Immun. 1982 Oct;38(1):103-8 [6890530.001]
  • [Cites] Ciba Found Symp. 1983;99:190-206 [6557014.001]
  • [Cites] J Immunol. 1986 Feb 1;136(3):1100-6 [3510253.001]
  • [Cites] Histochem J. 1986 Jan;18(1):5-14 [2423479.001]
  • [Cites] Am J Trop Med Hyg. 1986 Nov;35(6):1185-91 [3098125.001]
  • [Cites] J Immunol. 1990 Jan 1;144(1):317-22 [2153167.001]
  • [Cites] Pathol Res Pract. 1989 Dec;185(6):878-85 [2616372.001]
  • [Cites] Anal Quant Cytol Histol. 1992 Aug;14(4):312-9 [1388568.001]
  • [Cites] Carcinogenesis. 1997 Aug;18(8):1485-9 [9276620.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Indian J Pathol Microbiol. 2006 Jan;49(1):17-20 [16625965.001]
  • [Cites] BMC Gastroenterol. 2006;6:13 [16584555.001]
  • [Cites] Am J Trop Med Hyg. 2000 Sep-Oct;63(3-4):133-8 [11388504.001]
  • (PMID = 19659903.001).
  • [ISSN] 1365-2613
  • [Journal-full-title] International journal of experimental pathology
  • [ISO-abbreviation] Int J Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Helminth; 0 / Antigens, Nuclear; 0 / nucleolar organizer region associated proteins
  • [Other-IDs] NLM/ PMC2741155
  •  go-up   go-down


23. Loddenkemper C, Keller S, Hanski ML, Cao M, Jahreis G, Stein H, Zeitz M, Hanski C: Prevention of colitis-associated carcinogenesis in a mouse model by diet supplementation with ursodeoxycholic acid. Int J Cancer; 2006 Jun 1;118(11):2750-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 2 groups, the diet was supplemented with 0.2% cholic acid (CA), the precursor of DCA, or with 0.4% UDCA.
  • Among the animals fed the nonsupplemented diet, 46% developed colorectal adenocarcinomas and 54% anal-rectal squamous cell carcinomas.
  • The prevalence of dysplasia and carcinomas did not change significantly in the animals given CA.
  • Among the mice fed with UDCA, none developed adenocarcinomas and 20% squamous carcinomas.
  • The prevalence of dysplasia as well as of carcinoma showed an inverse relationship to the UDCA concentration in the fecal water.
  • [MeSH-major] Carcinoma / physiopathology. Carcinoma / prevention & control. Cholagogues and Choleretics / pharmacology. Colitis / complications. Colorectal Neoplasms / physiopathology. Colorectal Neoplasms / prevention & control. Diet. Ursodeoxycholic Acid / pharmacology
  • [MeSH-minor] Administration, Oral. Animals. Bile Acids and Salts / analysis. Cell Transformation, Neoplastic. Colon / chemistry. Colon / pathology. Disease Models, Animal. Female. Mice. Mice, Inbred C57BL

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16385573.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Cholagogues and Choleretics; 724L30Y2QR / Ursodeoxycholic Acid
  •  go-up   go-down


24. Trautmann TG, Zuger JH: Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol; 2005 Jul-Aug;7(4):309-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal.
  • PURPOSE: In recent years, combined modality therapy (CMT) with chemotherapy and radiation has replaced surgery as the preferred treatment for cancer of the anal canal.
  • PATIENTS AND METHODS: From September 1999 to August 2002, 21 patients with cancer of the anal canal were studied prospectively.
  • CONCLUSIONS: FDG-PET, in conjunction with CT scanning, provides additional staging information in cancer of the anal canal.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / diagnosis. Anus Neoplasms / pathology. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / diagnosis. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1999 Feb;70(2):71-7 [10084647.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):880-914 [11704310.001]
  • [Cites] Cancer Treat Rev. 2004 Feb;30(1):83-101 [14766127.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1034-9 [15020605.001]
  • [Cites] Eur J Nucl Med. 2000 May;27(5):590-4 [10853816.001]
  • [Cites] J Nucl Med. 1992 Nov;33(11):1972-80 [1432158.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):853-63 [14529793.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Ann Surg Oncol. 1997 Dec;4(8):613-20 [9416407.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):41-5 [10458216.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3995-4000 [14581422.001]
  • (PMID = 16028002.001).
  • [ISSN] 1536-1632
  • [Journal-full-title] Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • [ISO-abbreviation] Mol Imaging Biol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Chalastras T, Athanassiadou P, Patsouris E, Eleftheriadou A, Kandiloros D, Papaxoinis K, Nicolopoulou-Stamati P: Differential rates of proliferation and apoptosis in nasal polyps correspond to alterations in DNA spatial distribution and nuclear polarization as observed by confocal microscopy. Eur Arch Otorhinolaryngol; 2010 Jul;267(7):1075-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The polyps were classified according to their histological characteristics as: hyperplasia (simple and pronounced) and squamous metaplasia.
  • For each diagnosis, the rates were simple hyperplasia 60, 80 and 30%, pronounced hyperplasia 80, 100 and 40%, metaplasia 0, 0 and 100%, respectively.
  • [MeSH-major] Apoptosis / physiology. Carcinoma, Squamous Cell / pathology. DNA, Neoplasm / analysis. Ki-67 Antigen / analysis. Nasal Polyps / pathology. Precancerous Conditions / pathology. Proto-Oncogene Proteins c-bcl-2 / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Cell Proliferation. Chi-Square Distribution. Endoscopy. Female. Humans. Immunoenzyme Techniques. Male. Microscopy, Confocal. Middle Aged. Propidium. Tomography, X-Ray Computed

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rhinology. 1977 Jun;15(2):87-95 [918518.001]
  • [Cites] Anal Cell Pathol. 2000;20(4):187-95 [11205321.001]
  • [Cites] J Pathol. 1992 Apr;166(4):389-94 [1381431.001]
  • [Cites] Cell Oncol. 2005;27(5-6):335-45 [16373966.001]
  • [Cites] J Clin Pathol. 1997 Nov;50(11):923-8 [9462241.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):6961-5 [1871110.001]
  • [Cites] J Oral Pathol Med. 2005 Nov;34(10):602-7 [16202080.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Dec;113(6):724-32 [7501384.001]
  • [Cites] Acta Otolaryngol. 1996 Sep;116(5):755-61 [8908256.001]
  • [Cites] Anal Quant Cytol Histol. 1996 Aug;18(4):305-8 [8862673.001]
  • [Cites] Am J Rhinol. 2005 Nov-Dec;19(6):549-53 [16402639.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):237-41 [7812951.001]
  • [Cites] Rhinology. 1999 Dec;37(4):160-3 [10670029.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):417-23 [9130988.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Apr;122(4):432-6 [8600930.001]
  • [Cites] Lab Invest. 1995 Feb;72(2):191-200 [7531792.001]
  • [Cites] Head Neck. 1992 Nov-Dec;14(6):437-44 [1468914.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Mar;123(3):297-300 [9076236.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Jun;18(6):794-9 [9618384.001]
  • [Cites] Virchows Arch. 1997 Aug;431(2):111-7 [9293892.001]
  • [Cites] Am Rev Respir Dis. 1977 Oct;116(4):705-77 [921054.001]
  • [Cites] Am J Clin Pathol. 1981 Jun;75(6):816-21 [6167159.001]
  • (PMID = 20039176.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 36015-30-2 / Propidium
  •  go-up   go-down


26. Chan E, Kachnic LA, Thomas CR Jr: Anal cancer: progress on combined-modality and organ preservation. Curr Probl Cancer; 2009 Sep-Oct;33(5):302-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer: progress on combined-modality and organ preservation.
  • [MeSH-major] Anal Canal / surgery. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy / trends. Proctoscopy / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20082844.001).
  • [ISSN] 1535-6345
  • [Journal-full-title] Current problems in cancer
  • [ISO-abbreviation] Curr Probl Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  •  go-up   go-down


27. Oono Y, Fu K, Nakamura H, Iriguchi Y, Yamamura A, Kishi D, Oda J, Ikematsu H, Mizutani M, Takayanagi S, Tomino Y: Narrowband imaging colonoscopy with a transparent hood for diagnosis of a squamous cell carcinoma in situ in the anal canal. Endoscopy; 2010;42 Suppl 2:E183-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Narrowband imaging colonoscopy with a transparent hood for diagnosis of a squamous cell carcinoma in situ in the anal canal.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Colonoscopy / methods


28. Kauh J, Koshy M, Gunthel C, Joyner MM, Landry J, Thomas CR Jr: Management of anal cancer in the HIV-positive population. Oncology (Williston Park); 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anal cancer in the HIV-positive population.
  • Squamous cell anal cancer remains an uncommon entity; however, the incidence appears to be increasing in at-risk populations, especially those infected with human papillomavirus (HPV) and human immunodeficiency virus (HIV).
  • Given the ability to cure this cancer using synchronous chemoradiotherapy, management practices of this disease are critical.
  • This article considers treatment strategies for HIV-positive patients with anal cancer, including the impact on chemoradiation-induced toxicities and the role of highly active antiretroviral therapy in the treatment of this patient population.
  • The impact of the immune system in patients with HIV and squamous cell carcinoma of the anus and the associated response to therapy remains unknown.
  • Continued studies and phase III trials will be needed to test new treatment strategies in HIV-infected patients with squamous cell cancer of the anus to determine which treatment protocols provide the greatest benefits.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / epidemiology. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / therapy. HIV Infections / epidemiology


29. Siyan W, Feng Y, Lichuan Z, Jiarui W, Yingyan W, Li J, Bingcheng L, Qi W: Application of microfluidic gradient chip in the analysis of lung cancer chemotherapy resistance. J Pharm Biomed Anal; 2009 Apr 5;49(3):806-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of microfluidic gradient chip in the analysis of lung cancer chemotherapy resistance.
  • The major challenge of chemotherapy is the disease resistance for many lung cancer patients.
  • This work aimed to study the correlation between the expression of Glucose Regulated Protein-78 (GRP78) and the resistance to anticancer drug VP-16 in human lung squamous carcinoma cell line SK-MES-1 using an integrated microfluidic gradient chip device.
  • Our results from this study confirmed the role of GRP78 played in the chemotherapy resistance to VP-16 in SK-MES-1 cell line, suggesting that the integrated microfluidic systems may be an unique approach for characterizing the cellular responses.
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Calcimycin / pharmacology. Cell Line, Tumor. Etoposide / pharmacology. Fluorescent Antibody Technique. Fluorescent Dyes. Heat-Shock Proteins / biosynthesis. Heat-Shock Proteins / genetics. Humans. Image Processing, Computer-Assisted. Indoles. Ionophores / pharmacology. Microfluidic Analytical Techniques. Reproducibility of Results

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19162424.001).
  • [ISSN] 1873-264X
  • [Journal-full-title] Journal of pharmaceutical and biomedical analysis
  • [ISO-abbreviation] J Pharm Biomed Anal
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Fluorescent Dyes; 0 / Heat-Shock Proteins; 0 / Indoles; 0 / Ionophores; 0 / molecular chaperone GRP78; 37H9VM9WZL / Calcimycin; 47165-04-8 / DAPI; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


30. Nilsson PJ, Lenander C, Rubio C, Auer G, Ljungqvist O, Glimelius B: Prognostic significance of Cyclin A in epidermoid anal cancer. Oncol Rep; 2006 Sep;16(3):443-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of Cyclin A in epidermoid anal cancer.
  • Ultimately aiming at a more individualized therapeutic approach in epidermoid anal cancer, this study explored the prognostic and predictive impact of a set of tumour markers.
  • From a population-based cohort of 276 patients with epidermoid anal cancer, treated according to prospective protocols, 215 pre-treatment biopsies were investigated using immunohistochemistry.
  • Cyclin A may be an indicator of radiosensitivity and a valuable prognostic marker in epidermoid anal cancer.
  • [MeSH-major] Anus Neoplasms / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Cyclin A / metabolism

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865241.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin A; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


31. Wood GA, Sauder BL: Sexual side effects in women with anal carcinoma. Oncol Nurs Forum; 2009 May;36(3):275-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sexual side effects in women with anal carcinoma.
  • [MeSH-major] Anus Neoplasms / nursing. Anus Neoplasms / psychology. Carcinoma, Squamous Cell / nursing. Carcinoma, Squamous Cell / psychology. Sexuality

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Sexual Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19403449.001).
  • [ISSN] 1538-0688
  • [Journal-full-title] Oncology nursing forum
  • [ISO-abbreviation] Oncol Nurs Forum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Vietharsdóttir H, Moeller PH, Jóhannsson J, Jónasson JG: [Anal cancer in Iceland 1987-2003. A population based study]. Laeknabladid; 2006 May;92(5):365-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cancer in Iceland 1987-2003. A population based study].
  • [Transliterated title] Carcinoma ani á Islandi 1987-2003 -- lýethgrundueth rannsókn.
  • OBJECTIVE: Anal cancer is a rare disease.
  • The aim of this study was to describe anal cancer in Iceland in 1987-2003 with respect to incidence, histologic type, treatment, recurrence rate and survival.
  • MATERIAL AND METHODS: This is a retrospective study in which all malignant anal tumours diagnosed in Iceland in the period 1987-2003 were reviewed with respect to patient outcome.
  • This is a nationwide, population-based study of malignant tumours of the anal region.
  • RESULTS: From 1987-2003 thirty-eight patients were diagnosed with anal cancer, 28 females and 10 males.
  • The average age at diagnosis was 63.4 years.
  • Age standardized incidence rates for anal cancer in Iceland were 0.3 (+/-0.2) of 100.000 males and 0.9 (+/-0.4) of 100.000 females.
  • Most patients had squamous cell carcinoma (n=30).
  • The remaining histologic types were malignant melanoma (n=3), adenosquamous carcinoma (n=1), adenocarcinoma (n=1), GIST (n=1) and undifferentiated carcinoma (n=2).
  • The duration of symptoms before diagnosis ranged from 2 weeks to 96 months (mean value 3.5 months).
  • Twelve patients had recurrent cancer.
  • The mean value of the time from diagnosis of the primary to the recurrent cancer was 15.6 months (range, 5.9-117).
  • Sixteen patients remain with disease and ten have died of anal cancer.
  • The five year survival rate for patients diagnosed in the years 1987 to 1998 is 75% but cancer-specific survival is 82%.
  • CONCLUSION: Age-standardized incidence for anal cancer in Iceland is similar to other regions.
  • Average age at diagnosis, male-female ratio and prognosis is similar to reports in other studies.
  • The proportion of adenocarcinoma of the anus is lower in Iceland than elsewhere.
  • [MeSH-major] Anus Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Aged. Carcinoma / epidemiology. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Squamous Cell / epidemiology. Defecation. Female. Gastrointestinal Hemorrhage / etiology. Humans. Iceland / epidemiology. Incidence. Male. Melanoma / epidemiology. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pain / etiology. Pruritus / epidemiology. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741319.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


33. Poschmann G, Sitek B, Sipos B, Ulrich A, Wiese S, Stephan C, Warscheid B, Klöppel G, Vander Borght A, Ramaekers FC, Meyer HE, Stühler K: Identification of proteomic differences between squamous cell carcinoma of the lung and bronchial epithelium. Mol Cell Proteomics; 2009 May;8(5):1105-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of proteomic differences between squamous cell carcinoma of the lung and bronchial epithelium.
  • Proteins that exhibit different expression levels in normal and malignant lung cells are good candidate biomarkers to improve early diagnosis and intervention.
  • We used a quantitative approach and compared the proteome of microdissected cells from normal human bronchial epithelium and squamous cell carcinoma tumors of histopathological grades G2 and G3.
  • These proteins are mainly involved in energy pathways, cell growth or maintenance mechanisms, protein metabolism, and the regulation of DNA and RNA metabolism.
  • The expression of some of these proteins was analyzed by immunohistochemistry using tissue microarrays containing tissue specimen of 55 patients, including normal bronchial epithelium, squamous cell carcinomas, adenocarcinomas, and large cell carcinomas.
  • The results of the immunohistochemical studies correlated with the proteome study data and revealed that particularly HSP47 and a group of cytokeratins (i.e. cytokeratins 6a, 16, and 17) are significantly co-regulated in squamous cell carcinoma.
  • Furthermore cytokeratin 17 showed significantly higher abundance in G2 grade compared with G3 grade squamous cell carcinomas in both the gel-based and the immunohistochemical analysis.
  • [MeSH-major] Bronchi / metabolism. Carcinoma, Squamous Cell / metabolism. Epithelium / metabolism. Lung Neoplasms / metabolism. Proteome / analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2003 Apr 4;303(2):413-8 [12659832.001]
  • [Cites] Mol Cell Proteomics. 2005 Oct;4(10):1480-6 [15970581.001]
  • [Cites] Proteomics. 2006 Jan;6(2):547-58 [16342241.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):429-37 [16415791.001]
  • [Cites] J Invest Dermatol. 2006 Apr;126(4):869-81 [16470182.001]
  • [Cites] Nature. 2006 May 18;441(7091):362-5 [16710422.001]
  • [Cites] Oncol Rep. 2006 Sep;16(3):587-95 [16865260.001]
  • [Cites] Proteomics. 2006 Sep;6(18):5015-29 [16927432.001]
  • [Cites] Adv Clin Chem. 2006;42:1-41 [17131623.001]
  • [Cites] Cell Metab. 2008 Jan;7(1):11-20 [18177721.001]
  • [Cites] Proteomics. 2005 Mar;5(4):846-52 [15759313.001]
  • [Cites] Electrophoresis. 1999 Dec;20(18):3551-67 [10612281.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2000 Apr;109(4):401-10 [10778896.001]
  • [Cites] Anal Chem. 2000 Jun 1;72(11):2482-9 [10857624.001]
  • [Cites] Chest. 2000 Jun;117(6):1568-71 [10858384.001]
  • [Cites] Pathol Res Pract. 2000;196(10):665-73 [11087053.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):52-9 [12109856.001]
  • [Cites] Lung Cancer. 2003 Feb;39(2):131-8 [12581564.001]
  • [Cites] Electrophoresis. 1997 Mar-Apr;18(3-4):533-7 [9150937.001]
  • [Cites] Virchows Arch. 1998 May;432(5):455-60 [9645446.001]
  • [Cites] Nephron. 1998 Dec;80(4):434-43 [9832643.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2237-46 [9815620.001]
  • [Cites] Subcell Biochem. 1998;31:205-62 [9932494.001]
  • [Cites] Kidney Int Suppl. 1999 Jul;71:S256-9 [10412793.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:107-18 [15574354.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Eur J Cell Biol. 2004 Dec;83(11-12):735-46 [15679118.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):481-8 [15718248.001]
  • [Cites] Proteomics. 2004 Sep;4(9):2541-4 [15352228.001]
  • [Cites] Proteomics. 2004 Sep;4(9):2776-88 [15352251.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(2):127-47 [2424168.001]
  • [Cites] Environ Health Perspect. 1989 Mar;80:209-20 [2538323.001]
  • [Cites] Am J Physiol. 1990 Aug;259(2 Pt 1):L38-46 [2200283.001]
  • [Cites] J Cell Biol. 1992 May;117(4):903-14 [1577863.001]
  • [Cites] Am J Pathol. 1993 Feb;142(2):403-12 [7679549.001]
  • [Cites] Anal Chem. 1995 Apr 15;67(8):1426-36 [7741214.001]
  • [Cites] Electrophoresis. 1995 Jun;16(6):1034-59 [7498127.001]
  • [Cites] Anal Chem. 1995 Sep 15;67(18):3202-10 [8686885.001]
  • [Cites] Connect Tissue Res. 1996;33(4):265-73 [8834444.001]
  • [Cites] Lab Invest. 2005 Jun;85(6):789-97 [15806139.001]
  • [Cites] Proteomics. 2005 Jul;5(10):2665-79 [15924292.001]
  • [Cites] Oncologist. 2005 Aug;10(7):501-7 [16079317.001]
  • [Cites] J Drug Target. 2003 Feb;11(2):101-7 [12881196.001]
  • (PMID = 19176476.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-17; 0 / Neoplasm Proteins; 0 / Proteome
  • [Other-IDs] NLM/ PMC2689775
  •  go-up   go-down


34. Moon KY: The chemopreventive effect of retinoids on cellular NF-kappaB activity induced by NMU and NEU in human malignant keratinocytes. Cancer Res Treat; 2007 Jun;39(2):82-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to determine the implications of NF-kappaB activation on the chemopreventive role of retinoids and their effect on cellular NF-kappaB activity that's induced by known alkylating chemical carcinogens such as NMU and NEU in human transfectant squamous cell carcinoma (SCC-13) cells.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1980 Nov;22(2 Pt 2):629-32 [6160916.001]
  • [Cites] Nature. 1985 May 30-Jun 5;315(6018):382-5 [3923365.001]
  • [Cites] Curr Cancer Drug Targets. 2004 May;4(3):285-98 [15134535.001]
  • [Cites] Biol Pharm Bull. 2003 Aug;26(8):1195-7 [12913277.001]
  • [Cites] J Surg Res. 2002 Apr;103(2):183-9 [11922733.001]
  • [Cites] J Neurosci Res. 2002 Mar 1;67(5):670-9 [11891779.001]
  • [Cites] Immunopharmacol Immunotoxicol. 2001 Aug;23(3):335-42 [11694025.001]
  • [Cites] Anal Biochem. 2001 May 1;292(1):17-21 [11319812.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1085-9 [11007945.001]
  • [Cites] Cell Signal. 2006 Jun;18(6):889-98 [16176868.001]
  • [Cites] Radiat Res. 2005 Mar;163(3):296-306 [15733037.001]
  • [Cites] Adv Immunol. 1997;65:111-37 [9238509.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1081-5 [9067275.001]
  • [Cites] J Mol Med (Berl). 1996 Dec;74(12):749-69 [8974017.001]
  • [Cites] FASEB J. 1996 Jul;10(9):1031-9 [8801164.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):976-80 [7906199.001]
  • [Cites] Biochem Pharmacol. 1994 Jan 13;47(1):145-9 [8311838.001]
  • [Cites] Cancer Res. 1988 Sep 1;48(17):4827-33 [3409223.001]
  • [Cites] Cancer Treat Rep. 1987 Apr;71(4):391-405 [3548957.001]
  • [Cites] Nature. 1987 Dec 17-23;330(6149):624-9 [2825036.001]
  • [Cites] Nature. 1988 Jun 16;333(6174):669-72 [2836738.001]
  • [Cites] Ann Intern Med. 1987 Oct;107(4):499-502 [3477106.001]
  • [Cites] Cancer Res. 1983 Feb;43(2):829-33 [6848195.001]
  • (PMID = 19746216.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2739321
  • [Keywords] NOTNLM ; Chemoprevention / Human keratinocytes / NEU / NF-κB / NMU / Retinoids
  •  go-up   go-down


35. Fritsch H, Zehm S, Illig R, Moser P, Aigner F: New insights into the development and differentiation of the human anorectal epithelia. Are there clinical consequences? Int J Colorectal Dis; 2010 Oct;25(10):1231-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The epithelial lining of the anorectum still raises discussions concerning the levels of transition between the various zones and leads to an incomplete understanding of the immmunoprofile of rectal carcinoma.
  • Since the expression of cytokeratins depends on the epithelial cell-type and the parahox-gene CDX2 is important for the development of the colorectal epithelium, we investigated different cytokeratins and CDX2 in the anorectum of human prenatal stages and in adult normal and neoplastic anorecta.
  • In comparison, 17 specimens of ultralow rectal adenocarcinoma and 4 specimens of anal carcinoma were investigated.
  • We showed that anorectal epithelial differentiation including the squamous epithelia ran in a craniocaudal direction, and that the anorectal zone was a transitional zone between rectal zone and anal transitional zone where CK 7, 18, 20 and CDX2 are simultaneously expressed.
  • All cases of rectal adenocarcinoma showed positivity for CK 18, 20 and CDX2, and three also labelled for CK 7, whereas CK 14 was only expressed in the cases of anal carcinoma.
  • CONCLUSIONS: Our results elucidate the connection between the prenatal pattern and the origin of the different types of anorectal carcinoma.
  • [MeSH-major] Anal Canal / growth & development. Epithelial Cells / cytology. Epithelium / pathology. Rectum / growth & development
  • [MeSH-minor] Adult. Anus Neoplasms / pathology. Child, Preschool. Fetus / cytology. Homeodomain Proteins. Humans. Rectal Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2000 Apr;85(6):728-34 [10759675.001]
  • [Cites] Anat Rec (Hoboken). 2009 Jul;292(7):951-4 [19496155.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):303-10 [12604886.001]
  • [Cites] Folia Morphol (Warsz). 2003;62(3):285-7 [14507068.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1392-9 [15205684.001]
  • [Cites] J Pediatr Surg. 1974 Oct;9(5):755-69 [4424274.001]
  • [Cites] Cell. 1982 Sep;30(2):361-72 [6183000.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Dec;18(12):1251-7 [6187573.001]
  • [Cites] J Invest Dermatol. 1983 Jul;81(1 Suppl):109s-15s [6190956.001]
  • [Cites] Crit Rev Oncol Hematol. 1985;3(3):191-204 [2412718.001]
  • [Cites] Veroff Pathol. 1993;142:1-197 [7504860.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):586-92 [7677172.001]
  • [Cites] Arch Pathol Lab Med. 1997 Jul;121(7):719-23 [9240908.001]
  • [Cites] Adv Anat Embryol Cell Biol. 2005;177:1-131 [15615037.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Anat Rec (Hoboken). 2007 Nov;290(11):1449-58 [17853405.001]
  • [Cites] Oncogene. 2008 Jan 3;27(1):107-15 [17599044.001]
  • [Cites] Ann Anat. 2008;190(2):119-28 [18413265.001]
  • [Cites] Histol Histopathol. 2008 Sep;23(9):1043-7 [18581275.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2009 May;17(3):196-201 [19098678.001]
  • [Cites] Dev Cell. 2009 Apr;16(4):588-99 [19386267.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):141-9 [12548159.001]
  • (PMID = 20563874.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  • [Other-IDs] NLM/ PMC2928443
  •  go-up   go-down


36. Phan LK, Hoff PM: Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis Colon Rectum; 2007 Mar;50(3):395-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case.
  • Because of the high cure rate of localized anal cancers from combined modality treatment, there is little that is known for the treatment of patients who progress to have metastatic disease.
  • We report a female patient with refractory anal cancer who achieved an excellent response to the combination of cetuximab and irinotecan after having failed single-agent irinotecan.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252287.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 7673326042 / irinotecan; PQX0D8J21J / Cetuximab; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


37. Planque C, Kulasingam V, Smith CR, Reckamp K, Goodglick L, Diamandis EP: Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics; 2009 Dec;8(12):2746-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines.
  • Detection of lung cancer at an early stage is necessary for successful therapy and improved survival rates.
  • We performed a bottom-up proteomics analysis using a two-dimensional LC-MS/MS strategy on the conditioned media of four lung cancer cell lines of different histological backgrounds (non-small cell lung cancer: H23 (adenocarcinoma), H520 (squamous cell carcinoma), and H460 (large cell carcinoma); small cell lung cancer: H1688) to identify secreted or membrane-bound proteins that could be useful as novel lung cancer biomarkers.
  • We also identified known or putative lung cancer tumor markers such as squamous cell carcinoma antigen, carcinoembryonic antigen, chromogranin A, creatine kinase BB, progastrin-releasing peptide, neural cell adhesion molecule, and tumor M2-PK.
  • To select the most promising candidates for validation, we performed tissue specificity assays, functional classifications, literature searches for association to cancer, and a comparison of our proteome with the proteome of lung-related diseases and serum.
  • Five novel lung cancer candidates, ADAM-17, osteoprotegerin, pentraxin 3, follistatin, and tumor necrosis factor receptor superfamily member 1A were preliminarily validated in the serum of patients with lung cancer and healthy controls.
  • Our results demonstrate the utility of this cell culture proteomics approach to identify secreted and shed proteins that are potentially useful as serological markers for lung cancer.
  • [MeSH-minor] ADAM Proteins / metabolism. Animals. CHO Cells. Cell Line, Tumor. Chromatography, Liquid. Cricetinae. Cricetulus. Extracellular Space / metabolism. Humans. Mass Spectrometry. Membrane Proteins / metabolism. Neoplasm Proteins / chemistry. Neoplasm Proteins / classification. Neoplasm Proteins / metabolism. Proteome / chemistry. Proteome / metabolism. Reproducibility of Results

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proteomics. 2006 Dec;6(23):6354-69 [17133372.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7009-17 [17145822.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2405-22 [17110383.001]
  • [Cites] J Proteome Res. 2007 Mar;6(3):1083-92 [17284061.001]
  • [Cites] J Proteome Res. 2007 Dec;6(12):4615-23 [17973440.001]
  • [Cites] Cancer. 2007 Dec 15;110(12):2793-8 [17941001.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):660-7 [18245525.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1355-62 [18316555.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2326-33 [18413821.001]
  • [Cites] Ann Oncol. 2008 Jun;19(6):1075-81 [18238782.001]
  • [Cites] J Proteome Res. 2008 Aug;7(8):3329-38 [18578523.001]
  • [Cites] Biol Chem. 2008 Jun;389(6):781-6 [18627302.001]
  • [Cites] J Biol Chem. 2007 Mar 16;282(11):8325-31 [17227756.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2335-43 [17438092.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1039-49 [17277044.001]
  • [Cites] Cancer Sci. 2007 Aug;98(8):1265-74 [17537172.001]
  • [Cites] J Proteome Res. 2007 Jul;6(7):2859-65 [17567164.001]
  • [Cites] Endocrinology. 1999 Nov;140(11):5303-9 [10537161.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):5053-8 [11326667.001]
  • [Cites] Lung Cancer. 2001 May;32(2):137-44 [11325484.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2B):1241-6 [11396194.001]
  • [Cites] Electrophoresis. 2001 Oct;22(17):3629-38 [11699900.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2306-10 [12114435.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Eur Respir J. 2003 Mar;21(3):414-20 [12661994.001]
  • [Cites] Nature. 2003 Oct 30;425(6961):905 [14586448.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):347-55 [14729644.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):399-409 [14726492.001]
  • [Cites] Biomarkers. 2004 Jan-Feb;9(1):56-70 [15204311.001]
  • [Cites] Proteomics. 2004 Jul;4(7):1985-8 [15221759.001]
  • [Cites] Clin Chem. 2007 Aug;53(8):1423-32 [17573418.001]
  • [Cites] Mol Cell Proteomics. 2007 Aug;6(8):1406-15 [17495049.001]
  • [Cites] Mol Cell Proteomics. 2007 Nov;6(11):1997-2011 [17656355.001]
  • [Cites] Lung. 2008 Sep-Oct;186(5):323-6 [18663529.001]
  • [Cites] J Proteome Res. 2006 Oct;5(10):2743-53 [17022645.001]
  • [Cites] Clin Biochem. 2004 Sep;37(9):823-9 [15329323.001]
  • [Cites] Oncogene. 2004 Sep 23;23(44):7366-77 [15326482.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1794-802 [15386310.001]
  • [Cites] Int J Cancer. 2004 Dec 20;112(6):927-33 [15386364.001]
  • [Cites] Neoplasma. 1991;38(2):129-35 [1645850.001]
  • [Cites] Neoplasma. 1991;38(6):645-51 [1766488.001]
  • [Cites] Hum Pathol. 1992 Mar;23(3):312-6 [1313391.001]
  • [Cites] J Biol Chem. 1992 Nov 5;267(31):22190-7 [1429570.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):418-25 [8391379.001]
  • [Cites] Int J Cancer Suppl. 1994;8:49-52 [7515029.001]
  • [Cites] Endocrinology. 1996 Feb;137(2):486-94 [8593793.001]
  • [Cites] Br J Cancer. 1996 May;73(10):1227-32 [8630283.001]
  • [Cites] Exp Cell Res. 1996 Sep 15;227(2):230-9 [8831561.001]
  • [Cites] Prostate. 1997 Aug 1;32(3):214-20 [9254901.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Nov;82(11):3851-8 [9360551.001]
  • [Cites] Proteomics. 2005 Apr;5(6):1714-28 [15800970.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1073-85 [16083256.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1274-86 [16083277.001]
  • [Cites] Proteomics. 2005 Jul;5(11):2949-59 [15996010.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3475-90 [16047398.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1251-64 [15951573.001]
  • [Cites] Mol Cell Proteomics. 2005 Oct;4(10):1480-6 [15970581.001]
  • [Cites] Mol Cell Proteomics. 2005 Nov;4(11):1826-30 [16103422.001]
  • [Cites] Respir Res. 2005;6:118 [16236163.001]
  • [Cites] Tumour Biol. 2006;27(1):8-16 [16340245.001]
  • [Cites] Cancer Cell. 2006 Jul;10(1):39-50 [16843264.001]
  • [Cites] Proteomics. 2006 Aug;6(15):4390-401 [16819730.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):87-94 [16876904.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):95-102 [16890323.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1727-44 [16887931.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1921-6 [16896060.001]
  • (PMID = 19776420.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Culture Media, Conditioned; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Proteome; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / tumor necrosis factor-alpha convertase
  • [Other-IDs] NLM/ PMC2816016
  •  go-up   go-down


38. Harris AT, Rennie A, Waqar-Uddin H, Wheatley SR, Ghosh SK, Martin-Hirsch DP, Fisher SE, High AS, Kirkham J, Upile T: Raman spectroscopy in head and neck cancer. Head Neck Oncol; 2010 Oct 05;2:26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Raman spectroscopy in head and neck cancer.
  • In recent years there has been much interest in the use of optical diagnostics in cancer detection.
  • Early diagnosis of cancer affords early intervention and greatest chance of cure.
  • Raman has been used successfully in key health areas such as cardiovascular diseases, and dental care but there is a paucity of literature on Raman spectroscopy in Head and Neck cancer.
  • Following the introduction of health care targets for cancer, and with an ever-aging population the need for rapid cancer detection has never been greater.
  • Raman spectroscopy could confer great patient benefit with early, rapid and accurate diagnosis.
  • It could reduce the need for whole pathological specimen examination, in theatre it could help to determine margin status, and finally peripheral blood diagnosis may be an achievable target.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Phys Med Biol. 2000 Feb;45(2):R1-59 [10701500.001]
  • [Cites] Eur J Med Res. 2010 Mar 30;15(3):131-4 [20452899.001]
  • [Cites] Laryngoscope. 2000 Oct;110(10 Pt 1):1756-63 [11037840.001]
  • [Cites] Br J Dermatol. 2002 Mar;146(3):448-57 [11952545.001]
  • [Cites] J Biomed Opt. 2003 Jan;8(1):121-47 [12542388.001]
  • [Cites] Lasers Surg Med. 2003;32(3):210-4 [12605428.001]
  • [Cites] Gastrointest Endosc. 2003 Mar;57(3):396-402 [12612529.001]
  • [Cites] Photochem Photobiol. 2003 Aug;78(2):197-204 [12945589.001]
  • [Cites] Anal Chem. 2003 Dec 1;75(23):6679-86 [14640745.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):443-9 [15009728.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):59-68 [15047215.001]
  • [Cites] J Cell Biochem. 2004 Aug 15;92(6):1180-92 [15258901.001]
  • [Cites] Bioinformatics. 2005 Apr 1;21(7):860-8 [15513990.001]
  • [Cites] Lasers Surg Med. 2005 Sep;37(3):192-200 [16127671.001]
  • [Cites] Biopolymers. 2006 Feb 15;81(3):179-93 [16231284.001]
  • [Cites] Oral Oncol. 2006 Mar;42(3):221-8 [16140566.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3317-22 [16540686.001]
  • [Cites] J Biomed Opt. 2006 Mar-Apr;11(2):021003 [16674178.001]
  • [Cites] Bioinformatics. 2006 Oct 15;22(20):2565-6 [16882648.001]
  • [Cites] Biochem Soc Trans. 2007 Jun;35(Pt 3):544-9 [17511648.001]
  • [Cites] Int J Nanomedicine. 2007;2(4):785-98 [18203445.001]
  • [Cites] Analyst. 2008 Oct;133(10):1416-23 [18810290.001]
  • [Cites] Biopolymers. 2009 Jul;91(7):539-46 [19226625.001]
  • [Cites] Head Neck Oncol. 2009;1:25 [19594907.001]
  • [Cites] Head Neck Oncol. 2009;1:34 [19761601.001]
  • [Cites] Head Neck Oncol. 2009;1:38 [19863815.001]
  • [Cites] Oral Oncol. 2009 Dec;45(12):1006-10 [19828359.001]
  • [Cites] Int J Gynecol Cancer. 2010 Feb;20(2):283-7 [20134271.001]
  • [Cites] Expert Rev Anticancer Ther. 2010 Mar;10(3):321-9 [20214513.001]
  • [Cites] Anal Chem. 2000 Aug 15;72(16):3771-5 [10959962.001]
  • (PMID = 20923567.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2958871
  •  go-up   go-down


39. Allal AS, Bründler MA, Gervaz P: Differential expression of anti-apoptotic protein Bcl-2 in keratinizing versus non-keratinizing squamous cell carcinoma of the anus. Int J Colorectal Dis; 2005 Mar;20(2):161-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of anti-apoptotic protein Bcl-2 in keratinizing versus non-keratinizing squamous cell carcinoma of the anus.
  • BACKGROUND: Histologically, tumors of the anal region are either keratinizing (K) or non-keratinizing (NK) squamous cell carcinomas (SCCA).
  • METHODS: We performed an immunohistochemical analysis on 98 pre-treatment biopsies of patients with anal canal cancers.
  • The more distal the tumor is (anal margin), the more frequently the keratinizing subtype is observed (87 vs. 23%, p=0.0002).
  • [MeSH-major] Anus Neoplasms / metabolism. Apoptosis. Carcinoma, Squamous Cell / metabolism. Keratinocytes / pathology. Proto-Oncogene Proteins c-bcl-2 / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):494-505 [9358099.001]
  • [Cites] Pathology. 2002 Dec;34(6):573-8 [12555997.001]
  • [Cites] Br J Cancer. 1998 Jul;78(2):210-4 [9683295.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2001 Aug;97(2):223-30 [11451553.001]
  • [Cites] Swiss Med Wkly. 2003 Jun 28;133(25-26):353-9 [12947531.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1141-51 [2599902.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2120-30 [8683245.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):214-9 [12562647.001]
  • [Cites] J Clin Pathol. 1997 Aug;50(8):625-34 [9301544.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):51-8 [14529662.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Curr Opin Oncol. 2000 Jul;12(4):345-52 [10888420.001]
  • [Cites] J Clin Pathol. 1997 Jan;50(1):33-6 [9059353.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):805-15 [9264365.001]
  • (PMID = 15688099.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


40. Saarilahti K, Arponen P, Vaalavirta L, Tenhunen M: The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol; 2008 Jun;87(3):383-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer.
  • BACKGROUND AND PURPOSE: To investigate acute and late radiotherapy-related adverse events following intensity-modulated radiotherapy (IMRT) and high dose rate (HDR) brachytherapy of anal cancer.
  • MATERIALS AND METHODS: Fifty-nine consecutive patients treated by chemoradiotherapy for anal squamous cell cancer were evaluated for acute and late radiotherapy-related adverse events.
  • A correlation between the equivalent dose in 2Gy fractions (EQD2) at the wall of anal canal opposite to the tumour and radiation proctitis was observed.
  • CONCLUSIONS: IMRT significantly reduces acute radiotherapy-associated adverse events in patients treated by chemoradiotherapy for anal cancer.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Brachytherapy / adverse effects. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy, Intensity-Modulated / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / radiotherapy. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiation Injuries. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501454.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


41. Milano MT, Jani AB, Farrey KJ, Rash C, Heimann R, Chmura SJ: Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys; 2005 Oct 1;63(2):354-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome.
  • PURPOSE: To assess survival, local control, and toxicity of intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the anal canal.
  • CONCLUSIONS: In this hypothesis-generating analysis, the acute toxicity and clinical outcome with IMRT in the treatment of anal cancer is encouraging.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy, Conformal / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168830.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


42. Ferrigno R, Nakamura RA, Dos Santos Novaes PE, Pellizzon AC, Maia MA, Fogarolli RC, Salvajoli JV, Filho WJ, Lopes A: Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys; 2005 Mar 15;61(4):1136-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
  • PURPOSE: This retrospective analysis reports the results on patients with anal canal carcinoma treated by combined radiotherapy and chemotherapy.
  • METHODS AND MATERIALS: Between March 1993 and December 2001, 43 patients with anal canal carcinoma were treated with radiochemotherapy at the Hospital do Cancer A.C. Camargo.
  • CONCLUSIONS: This analysis suggests that the treatment scheme employed was effective for anal sphincter preservation and local control; however, the incidence of distant metastases was relatively high.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15752894.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


43. Shiozawa M, Nishimura K, Nonaka T, Yoshii T, Nakayama N, Motohashi O, Takagi S, Nakayama Y, Akaike M: [Three cases of radiotherapy combined with S-1 and mitomycin C for anal canal squamous cell carcinomas]. Gan To Kagaku Ryoho; 2010 Dec;37(13):2941-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three cases of radiotherapy combined with S-1 and mitomycin C for anal canal squamous cell carcinomas].
  • We report three cases of anal canal squamous cell carcinoma treated with radiotherapy combined with S-1 and mitomycin C(MMC).
  • These results suggested that this treatment schedule was safe and effective for anal canal carcinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Administration, Oral. Aged. Anal Canal. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Injections, Intravenous. Middle Aged. Mitomycin / administration & dosage. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160276.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


44. Wang Z, Jiang L, Huang C, Li Z, Chen L, Gou L, Chen P, Tong A, Tang M, Gao F, Shen J, Zhang Y, Bai J, Zhou M, Miao D, Chen Q: Comparative proteomics approach to screening of potential diagnostic and therapeutic targets for oral squamous cell carcinoma. Mol Cell Proteomics; 2008 Sep;7(9):1639-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative proteomics approach to screening of potential diagnostic and therapeutic targets for oral squamous cell carcinoma.
  • This work demonstrates that a comprehensive strategy of proteomics identification combined with further validation and detailed functional analysis should be adopted in the field of cancer biomarker discovery.
  • A comparative proteomics approach was utilized to identify differentially expressed proteins in 10 oral squamous carcinoma samples paired with their corresponding normal tissues.
  • A total of 52 significantly and consistently altered proteins were identified with eight of these being reported for the first time in oral squamous carcinoma.
  • RACK1 was demonstrated to be up-regulated in cancer at both the mRNA and protein levels.
  • Immunohistochemical examination showed that the enhanced expression of RACK1 was correlated with the severity of the epithelial dysplasia as well as clinical stage, lymph node involvement, and recurrence, which are known indicators of a relatively poor prognosis in oral squamous carcinoma patients.
  • RNA interference specifically targeted to silence RACK1 could initiate apoptosis of oral squamous carcinoma cells.
  • Taken together, the results indicate that RACK1 is up-regulated in oral squamous carcinoma, not only being closely related to cell proliferation and apoptosis but also linked to clinical invasiveness and metastasis in carcinogenesis.
  • The observations suggest that RACK1 may be a potential biomarker for early diagnosis, prognosis, and monitoring in the therapy of oral squamous carcinoma.
  • Further this comprehensive strategy could be used for identifying other differentially expressed proteins that have potential to be candidate biomarkers of oral squamous carcinoma.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Proteomics. 2003 Jun;2(6):378-87 [12813140.001]
  • [Cites] Proteomics. 2004 Jan;4(1):271-8 [14730689.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:295-305 [15251975.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5232-6 [15289328.001]
  • [Cites] Oncol Res. 2004;14(10):491-9 [15559763.001]
  • [Cites] Gene Ther. 2005 Jan;12(1):5-11 [15496962.001]
  • [Cites] Cell Cycle. 2004 Oct;3(10):1285-95 [15467455.001]
  • [Cites] Anal Chem. 2005 May 1;77(9):2745-55 [15859589.001]
  • [Cites] Med J Aust. 2005 Jun 6;182(11):575-9 [15938685.001]
  • [Cites] Head Neck. 2005 Nov;27(11):995-1003 [16200629.001]
  • [Cites] Electrophoresis. 2006 Apr;27(7):1417-23 [16568407.001]
  • [Cites] Proteomics. 2006 Apr;6 Suppl 1:S262-71 [16534743.001]
  • [Cites] J Mol Neurosci. 2006;29(1):55-63 [16757810.001]
  • [Cites] Exp Mol Med. 2006 Jun 30;38(3):203-9 [16819278.001]
  • [Cites] Mol Cell Proteomics. 2006 Nov;5(11):2092-101 [16893879.001]
  • [Cites] Clin Chim Acta. 2007 Feb;376(1-2):101-7 [16889763.001]
  • [Cites] J Cancer Res Clin Oncol. 2007 Apr;133(4):253-61 [17136347.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):309-15 [17384585.001]
  • [Cites] J Proteome Res. 2007 Jun;6(6):2143-51 [17451265.001]
  • [Cites] Mol Cell Proteomics. 2007 Jun;6(6):987-99 [16829691.001]
  • [Cites] Eur J Biochem. 2000 Jun;267(12):3891-901 [10849009.001]
  • [Cites] FASEB J. 2000 Dec;14(15):2549-58 [11099474.001]
  • [Cites] Virology. 2001 Apr 25;283(1):7-18 [11312657.001]
  • [Cites] J Biol Chem. 2001 Jun 8;276(23):20346-56 [11279199.001]
  • [Cites] Cell Signal. 2001 Jul;13(7):507-13 [11516626.001]
  • [Cites] Dis Markers. 2001;17(2):49-57 [11673651.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(7):2345-65 [11884618.001]
  • [Cites] Head Neck. 2002 Feb;24(2):165-80 [11891947.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):698-704 [11902541.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] J Biol Chem. 2002 Jun 14;277(24):22073-84 [11934885.001]
  • [Cites] Mol Pharmacol. 2002 Dec;62(6):1261-73 [12435793.001]
  • [Cites] J Virol. 2002 Dec;76(24):12676-82 [12438593.001]
  • (PMID = 18458027.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / R21 AA021205
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GNB2L1 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; EC 3.6.1.- / GTP-Binding Proteins
  • [Other-IDs] NLM/ PMC2556024
  •  go-up   go-down


45. de Bree E, van Ruth S, Dewit LG, Zoetmulder FA: High risk of colostomy with primary radiotherapy for anal cancer. Ann Surg Oncol; 2007 Jan;14(1):100-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High risk of colostomy with primary radiotherapy for anal cancer.
  • BACKGROUND: Radiotherapy (RT) has become the primary treatment of choice for anal cancer in an effort to avoid colostomy.
  • RESULTS: Totally, 28 patients (34%) required creation of a colostomy after primary RT for local failure or treatment-related complications during a mean follow-up period of 39 months.
  • CONCLUSIONS: In approximately one-third of the patients treated by anal sphincter saving management with curative aimed primary RT, the creation of a colostomy appeared to be necessary for RT complications and local treatment failure.
  • Therefore, patients should be well informed regarding the considerable risk of need for colostomy after RT for anal cancer.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Colostomy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17066231.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A; 2007 Jan 16;104(3):973-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma.
  • Like many epithelial tumors, head and neck squamous cell carcinoma (HNSCC) contains a heterogeneous population of cancer cells.
  • We developed an immunodeficient mouse model to test the tumorigenic potential of different populations of cancer cells derived from primary, unmanipulated human HNSCC samples.
  • We show that a minority population of CD44(+) cancer cells, which typically comprise <10% of the cells in a HNSCC tumor, but not the CD44(-) cancer cells, gave rise to new tumors in vivo.
  • Immunohistochemistry revealed that the CD44(+) cancer cells have a primitive cellular morphology and costain with the basal cell marker Cytokeratin 5/14, whereas the CD44(-) cancer cells resemble differentiated squamous epithelium and express the differentiation marker Involucrin.
  • BMI1 has been demonstrated to play a role in self-renewal in other stem cell types and to be involved in tumorigenesis.
  • Taken together, these data demonstrate that cells within the CD44(+) population of human HNSCC possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation and form unique histological microdomains that may aid in cancer diagnosis.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Cell Pathol. 1999;19(2):53-8 [10746434.001]
  • [Cites] Genes Dev. 2005 Jun 15;19(12):1432-7 [15964994.001]
  • [Cites] N Engl J Med. 2001 Feb 22;344(8):601-2 [11207357.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • [Cites] Gene Ther. 2002 May;9(10):606-12 [12032706.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] Science. 2002 Sep 27;297(5590):2256-9 [12215650.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Nature. 2003 May 15;423(6937):255-60 [12714970.001]
  • [Cites] Nature. 2003 May 15;423(6937):302-5 [12714971.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Nature. 2003 Oct 30;425(6961):962-7 [14574365.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):175-9 [14722607.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):895-902 [14737120.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Cell. 2004 Aug 20;118(4):409-18 [15315754.001]
  • [Cites] Curr Probl Cancer. 2004 Sep-Oct;28(5):265-86 [15375804.001]
  • [Cites] J Pathol. 1985 Apr;145(4):329-40 [3889247.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3290-4 [1373493.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Blood. 1997 May 1;89(9):3104-12 [9129012.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):335-42 [9827902.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R605-15 [15535842.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] J Exp Med. 2005 May 16;201(10):1579-89 [15897275.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7521-6 [10861016.001]
  • (PMID = 17210912.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097248; United States / NCI NIH HHS / CA / 5P50 CA 097248
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44
  • [Other-IDs] NLM/ PMC1783424
  •  go-up   go-down


47. Steller W, Einenkel J, Horn LC, Braumann UD, Binder H, Salzer R, Krafft C: Delimitation of squamous cell cervical carcinoma using infrared microspectroscopic imaging. Anal Bioanal Chem; 2006 Jan;384(1):145-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delimitation of squamous cell cervical carcinoma using infrared microspectroscopic imaging.
  • Infrared (IR) spectroscopic imaging coupled with microscopy has been used to investigate thin sections of cervix uteri encompassing normal tissue, precancerous structures, and squamous cell carcinoma.
  • In the second step, analysis in the spectral window 1420-1480 cm(-1) enables, for the first time, IR spectroscopic distinction between the basal layer, dysplastic lesions and squamous cell carcinoma within a particular sample.
  • The joint application of IR microspectroscopic imaging and multivariate spectral processing combines diffraction-limited lateral optical resolution on the single cell level with highly specific and sensitive spectral classification on the molecular level.
  • Compared with previous reports our approach constitutes a significant progress in the development of optical molecular spectroscopic techniques toward an additional diagnostic tool for the early histopathological characterization of cervical cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Spectrophotometry, Infrared / methods. Uterine Cervical Neoplasms / pathology


48. Yildiz PB, Shyr Y, Rahman JS, Wardwell NR, Zimmerman LJ, Shakhtour B, Gray WH, Chen S, Li M, Roder H, Liebler DC, Bigbee WL, Siegfried JM, Weissfeld JL, Gonzalez AL, Ninan M, Johnson DH, Carbone DP, Caprioli RM, Massion PP: Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol; 2007 Oct;2(10):893-901
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer.
  • PURPOSE: There is a critical need for improvements in the noninvasive diagnosis of lung cancer.
  • We hypothesized that matrix-assisted laser desorption ionization mass spectrometry (MALDI MS) analysis of the most abundant peptides in the serum may distinguish lung cancer cases from matched controls.
  • The serum signature was associated with the diagnosis of lung cancer independently of gender, smoking status, smoking pack-years, and C-reactive protein levels.
  • From this signature, we identified three discriminatory features as members of a cluster of truncated forms of serum amyloid A.
  • CONCLUSIONS: We found a serum proteomic profile that discriminates lung cancer from matched controls.
  • Proteomic analysis of unfractionated serum may have a role in the noninvasive diagnosis of lung cancer and will require methodological refinements and prospective validation to achieve clinical utility.

  • Genetic Alliance. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909350.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / R33 CA086243; United States / NCI NIH HHS / CA / P50 CA090440; United States / NCI NIH HHS / CA / P50 CA090949-07; United States / NCI NIH HHS / CA / P50 CA90440; United States / NCI NIH HHS / CA / P50 CA090949; United States / NCI NIH HHS / CA / P30 CA068485; United States / NCI NIH HHS / CA / P50 CA90949; United States / NCI NIH HHS / CA / U01 CA114771-04; United States / NCI NIH HHS / CA / U01 CA114771; United States / NCI NIH HHS / CA / 5R33CA86243
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS637970; NLM/ PMC4220686
  •  go-up   go-down


49. Gretschel S, Warnick P, Bembenek A, Dresel S, Koswig S, String A, Hünerbein M, Schlag PM: Lymphatic mapping and sentinel lymph node biopsy in epidermoid carcinoma of the anal canal. Eur J Surg Oncol; 2008 Aug;34(8):890-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic mapping and sentinel lymph node biopsy in epidermoid carcinoma of the anal canal.
  • AIM: Although 15-25% of patients with anal cancer present with superficial inguinal lymph node metastases but the routine application of groin irradiation is controversial because of serious side effects.
  • METHODS: Forty patients with anal cancer underwent 1 ml Tc(99m)-Nanocolloid injection in four sites around the tumour.
  • CONCLUSIONS: Inguinal sentinel node biopsy in anal cancer is efficient and could assist in the decision for inguinal radiation.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / secondary. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18178364.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Technetium Tc 99m Aggregated Albumin
  •  go-up   go-down


50. Chang PL, Harkins L, Hsieh YH, Hicks P, Sappayatosok K, Yodsanga S, Swasdison S, Chambers AF, Elmets CA, Ho KJ: Osteopontin expression in normal skin and non-melanoma skin tumors. J Histochem Cytochem; 2008 Jan;56(1):57-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteopontin (OPN) is an adhesive, matricellular glycoprotein, whose expression is elevated in many types of cancer and has been shown to facilitate tumorigenesis in vivo.
  • To understand the role of OPN in human skin cancer, this study is designed to determine whether OPN is expressed in premalignant [solar/actinic keratosis (AK)] and in malignant skin lesions such as squamous cell carcinomas (SCC) and basal cell carcinomas (BCC), as well as in normal skin exposed or not exposed to sunlight.
  • In sunlight-exposed normal skin, OPN is minimally expressed in the basal cell layer, but in contrast to those not exposed to sunlight, OPN is more prominent in the spinous cell layer with increasing intensity toward the granular cell layer.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 1995 Feb;216(2):335-41 [7843278.001]
  • [Cites] Am J Pathol. 1995 Jan;146(1):95-100 [7856741.001]
  • [Cites] Arch Dermatol. 1995 Jul;131(7):796-800 [7611795.001]
  • [Cites] Matrix Biol. 1995 Jul;14(7):553-60 [8535605.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Lung Cancer. 1996 Nov;15(3):311-23 [8959677.001]
  • [Cites] Arch Biochem Biophys. 1997 Jul 15;343(2):157-63 [9224725.001]
  • [Cites] Cancer Invest. 1998;16(5):329-44 [9627681.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):136-42 [9627707.001]
  • [Cites] J Bone Miner Res. 1998 Jul;13(7):1101-11 [9661074.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):605-11 [9815727.001]
  • [Cites] Curr Opin Cell Biol. 1998 Oct;10(5):640-6 [9818175.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1250-4 [9824103.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1087-90 [9870857.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Mar;47(3):802-6 [16505010.001]
  • [Cites] J Pediatr Surg. 2006 Apr;41(4):624-32; discussion 624-32 [16567167.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):233-46 [16816376.001]
  • [Cites] Arch Dermatol. 2006 Jul;142(7):900-6 [16847207.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7119-27 [16849558.001]
  • [Cites] Zhonghua Wei Chang Wai Ke Za Zhi. 2007 Jan;10(1):73-6 [17253181.001]
  • [Cites] J Histochem Cytochem. 2007 Apr;55(4):403-9 [17210923.001]
  • [Cites] Pathol Res Pract. 1999;195(11):733-9 [10605692.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):156-63 [10901364.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jan 19;280(2):460-5 [11162539.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4060-6 [11751502.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):270-8 [11807984.001]
  • [Cites] J Invest Dermatol. 2001 Dec;117(6):1554-8 [11886522.001]
  • [Cites] J Oral Pathol Med. 1999 Mar;28(3):97-101 [10069535.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2271-7 [10473115.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Oct;160(4):1269-73 [10508818.001]
  • [Cites] Dent Mater J. 2004 Dec;23(4):650-5 [15688734.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3958-65 [15867397.001]
  • [Cites] Kidney Int. 2005 Jul;68(1):155-66 [15954904.001]
  • [Cites] Trends Cell Biol. 2006 Feb;16(2):79-87 [16406521.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2255-61 [16331611.001]
  • [Cites] Exp Cell Res. 2007 Apr 1;313(6):1149-60 [17306792.001]
  • [Cites] Oncogene. 2007 May 3;26(20):2840-50 [17160024.001]
  • [Cites] Bone. 2007 Jun;40(6):1517-28 [17395559.001]
  • [Cites] Diabetes. 2007 Jun;56(6):1662-70 [17360982.001]
  • [Cites] Clin Exp Metastasis. 2003;20(1):77-84 [12650610.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):119-27 [12833464.001]
  • [Cites] Protein Expr Purif. 2003 Aug;30(2):238-45 [12880773.001]
  • [Cites] Carcinogenesis. 2003 Nov;24(11):1749-58 [12919959.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90 [14734468.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):487-91 [15006928.001]
  • [Cites] Br J Cancer. 2004 May 17;90(10):1877-81 [15138464.001]
  • [Cites] J Dent Res. 2004 Sep;83(9):664-70 [15329369.001]
  • [Cites] J Surg Res. 2004 Oct;121(2):228-41 [15501463.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Oct;83(19):7182-6 [3532105.001]
  • [Cites] J Biol Chem. 1987 Feb 25;262(6):2900-7 [3469201.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] J Exp Med. 1989 Jul 1;170(1):145-61 [2787378.001]
  • [Cites] Genomics. 1989 Aug;5(2):375-7 [2571582.001]
  • [Cites] Anticancer Res. 1989 Sep-Oct;9(5):1291-9 [2686530.001]
  • [Cites] Genomics. 1990 Aug;7(4):491-502 [1974876.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2144-50 [2009532.001]
  • [Cites] Mol Carcinog. 1991;4(3):196-202 [2064725.001]
  • [Cites] J Bone Miner Res. 1992 Jul;7(7):743-54 [1642143.001]
  • [Cites] Mol Biol Cell. 1992 Oct;3(10):1169-80 [1421573.001]
  • [Cites] J Histochem Cytochem. 1994 Mar;42(3):351-61 [8308252.001]
  • [Cites] Endocrinology. 1994 Sep;135(3):863-9 [8070379.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):610-23 [8080043.001]
  • [Cites] Cancer. 1995 Jan 15;75(2 Suppl):607-12 [7804986.001]
  • [Cites] Lab Invest. 1995 Jan;72(1):55-63 [7837791.001]
  • [Cites] Lab Invest. 1995 Jan;72(1):64-9 [7837792.001]
  • [Cites] Cell Growth Differ. 1997 Oct;8(10):1061-9 [9342184.001]
  • [Cites] J Cell Biochem. 1997 Dec 1;67(3):386-96 [9361193.001]
  • [Cites] J Clin Invest. 1998 Apr 1;101(7):1468-78 [9525990.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):127-32 [9583725.001]
  • [Cites] J Biol Chem. 1994 Sep 16;269(37):23280-5 [8083234.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1671-9 [11926891.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):513-21 [11929952.001]
  • [Cites] J Am Soc Nephrol. 2002 May;13(5):1210-8 [11961008.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):506-12 [12209742.001]
  • (PMID = 17938278.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090920; United States / NCI NIH HHS / CA / R01 CA90920
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 106441-73-0 / Osteopontin
  • [Other-IDs] NLM/ PMC2323122
  •  go-up   go-down


51. Haboubi N: Anal cancer; do we all have a common treatment strategy? Colorectal Dis; 2009 Nov;11(9):891-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer; do we all have a common treatment strategy?
  • [MeSH-major] Adenocarcinoma / pathology. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19832862.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] England
  •  go-up   go-down


52. Oblak I, Petric P, Anderluh F, Velenik V, Hudej R, Fras AP: Anal cancer chemoirradiation with curative intent - a single institution experience. Neoplasma; 2009;56(2):150-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer chemoirradiation with curative intent - a single institution experience.
  • Results of radiochemotherapy in 50 patients with squamous cell carcinoma of the anal canal, treated with radical radiochemotherapy between January 2003 and September 2007, at the Institute of Oncology Ljubljana are presented.
  • Late anal stenosis, chronic ulceration and grade 2-3 incontinence developed in 3 (6 %), 2 (4 %) and 5 (10 %) of colostomy-free survivors, respectively.
  • </p> KEYWORDS: anal cancer, radiochemotherapy, survival, toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19239330.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


53. Ghouti L, Houvenaeghel G, Moutardier V, Giovannini M, Magnin V, Lelong B, Bardou VJ, Delpero JR: Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer. Dis Colon Rectum; 2005 Jan;48(1):16-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer.
  • PURPOSE: Radiotherapy alone or with combined chemotherapy is the first therapeutic option for epidermoid carcinoma of the anal canal.
  • CONCLUSIONS: Despite high incidence of perineal morbidity, salvage abdominoperineal resection for epidermoid carcinomas of the anal canal has a high long-term survival rate.
  • [MeSH-major] Abdomen / surgery. Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Perineum / surgery

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690652.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Manoharan S, Kavitha K, Balakrishnan S, Rajalingam K: Clerodendron inerme protects cellular integrity during 7,12-dimethylbenz[A]-anthracene induced hamster buccal pouch carcinogenesis. Afr J Tradit Complement Altern Med; 2008 Jan 22;5(2):213-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oral squamous cell carcinoma was induced in the buccal pouch of Syrian golden hamsters by painting with 0.5% DMBA in liquid paraffin thrice a week for 14 weeks.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 1973 Mar;19(3):338-40 [4347544.001]
  • [Cites] J Biol Chem. 1948 Sep;175(2):595-603 [18880756.001]
  • [Cites] Biochem Biophys Res Commun. 1980 Jan 29;92(2):631-7 [6766724.001]
  • [Cites] Res Commun Chem Pathol Pharmacol. 1980 Oct;30(1):171-80 [7433766.001]
  • [Cites] Cancer Detect Prev. 1998;22(3):237-40 [9618045.001]
  • [Cites] Int J Mol Med. 2000 Feb;5(2):201-5 [10639602.001]
  • [Cites] Oral Dis. 2000 Mar;6(2):65-74 [10702782.001]
  • [Cites] J Hematother Stem Cell Res. 2000 Apr;9(2):247-55 [10813538.001]
  • [Cites] J Dent Educ. 2001 Apr;65(4):328-39 [11336118.001]
  • [Cites] Jpn J Pharmacol. 2001 Jul;86(3):302-9 [11488430.001]
  • [Cites] Clin Chim Acta. 2002 Dec;326(1-2):143-9 [12417105.001]
  • [Cites] Clin Biochem. 2003 Feb;36(1):61-5 [12554062.001]
  • [Cites] Pharmacol Res. 2003 Aug;48(2):167-73 [12798669.001]
  • [Cites] J Biol Chem. 1957 May;226(1):497-509 [13428781.001]
  • [Cites] Clin Chim Acta. 2004 Jan;339(1-2):91-6 [14687898.001]
  • [Cites] Biomed Pharmacother. 2004 May;58(4):264-7 [15183854.001]
  • [Cites] J Lab Clin Med. 1950 Jan;35(1):155-60 [15400638.001]
  • [Cites] Clin Biochem. 2005 Jun;38(6):535-9 [15885233.001]
  • [Cites] J Clin Invest. 1947 Jul;26(4):636-40 [16695456.001]
  • [Cites] Singapore Med J. 2006 Dec;47(12):1038-43 [17139399.001]
  • [Cites] Clin Chim Acta. 1973 Jun 28;46(2):105-11 [4745354.001]
  • (PMID = 20161940.001).
  • [ISSN] 2505-0044
  • [Journal-full-title] African journal of traditional, complementary, and alternative medicines : AJTCAM
  • [ISO-abbreviation] Afr J Tradit Complement Altern Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Other-IDs] NLM/ PMC2816544
  • [Keywords] NOTNLM ; Clerodendron inerme / DMBA / Oral cancer / glycoconjugates / hamster / lipids / osmotic fragility
  •  go-up   go-down


55. Atkinson DM, Clarke MJ, Mladek AC, Carlson BL, Trump DP, Jacobson MS, Kemp BJ, Lowe VJ, Sarkaria JN: Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts. Head Neck; 2008 Jun;30(6):790-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2166-74 [10873065.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8558-64 [16951168.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3331-4 [12067968.001]
  • [Cites] J Nucl Med. 2002 Sep;43(9):1210-7 [12215561.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1462-9 [12397465.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3315-23 [12429617.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2681-7 [12750297.001]
  • [Cites] Gut. 2003 Nov;52(11):1602-6 [14570730.001]
  • [Cites] J Nucl Med. 2003 Dec;44(12):2027-32 [14660729.001]
  • [Cites] J Nucl Med. 2004 Apr;45(4):695-700 [15073267.001]
  • [Cites] Cell Res. 2004 Aug;14(4):295-302 [15353126.001]
  • [Cites] Acta Biol Med Ger. 1972;29(4):483-94 [4347226.001]
  • [Cites] J Biol Chem. 1991 May 15;266(14):9032-8 [2026611.001]
  • [Cites] Biochem Pharmacol. 1992 Jul 22;44(2):199-204 [1322661.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1334-6 [9809561.001]
  • [Cites] J Nucl Med. 2005 Jan;46(1):114-20 [15632041.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3003-10 [15833824.001]
  • [Cites] Anal Cell Pathol. 2001;23(1):11-9 [11790855.001]
  • (PMID = 18286491.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108961; United States / NCI NIH HHS / CA / R21 CA104310; United States / NCI NIH HHS / CA / CA0108961; United States / NCI NIH HHS / CA / CA104310; United States / NCI NIH HHS / CA / CA25224; United States / NCI NIH HHS / CA / U10 CA025224
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Dideoxynucleosides; 0 / Fluorine Radioisotopes; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PG53R0DWDQ / alovudine; PQX0D8J21J / Cetuximab
  • [Other-IDs] NLM/ NIHMS548870; NLM/ PMC3942889
  •  go-up   go-down


56. Jongen J: Letter to the editor concerning "HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN)" by Varnai et al. (Int J Colorectal Dis 21:135-142, 2006). Int J Colorectal Dis; 2007 Oct;22(10):1289
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Letter to the editor concerning "HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN)" by Varnai et al. (Int J Colorectal Dis 21:135-142, 2006).
  • [MeSH-major] Alphapapillomavirus / isolation & purification. Anus Neoplasms / virology. Carcinoma in Situ / virology. Carcinoma, Squamous Cell / virology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Int J Colorectal Dis. 2006 Mar;21(2):135-42 [15864603.001]
  • (PMID = 16703315.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Germany
  •  go-up   go-down


57. Amano K, Ishibashi K, Nakada H, Okada N, Miyazaki T, Gonda T, Ishida H, Takahashi T: [Squamous cell carcinoma of the anal canal in the elderly showing complete response following radiotherapy--a case report]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2025-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the anal canal in the elderly showing complete response following radiotherapy--a case report].
  • We reported an elderly case of squamous cell carcinoma of the anal canal which showed complete response following radiotherapy alone.
  • An 86-year-old man complaining of anal bleeding and pain was admitted.
  • Biopsy revealed squamous cell carcinoma.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219887.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


58. Sameer AS, Chowdri NA, Syeed N, Banday MZ, Shah ZA, Siddiqi MA: SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene. BMC Cancer; 2010;10:300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene.
  • BACKGROUND: The development and progression of colorectal cancer has been extensively studied and the genes responsible have been well characterized.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. Colorectal Neoplasms / genetics. Mutation. Proto-Oncogene Proteins / genetics. Signal Transduction. Smad4 Protein / genetics. Transforming Growth Factor beta / metabolism. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] Mol Cell Biochem. 2009 Dec;332(1-2):51-8 [19513816.001]
  • [Cites] Carcinogenesis. 1992 Aug;13(8):1331-5 [1499084.001]
  • [Cites] Curr Opin Oncol. 1993 Jan;5(1):123-9 [8427884.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2527-30 [8653691.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):347-9 [8673135.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3130-46 [17114584.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):21-62 [16904831.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):229-43 [17349581.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):295-308 [17384584.001]
  • [Cites] Environ Health Perspect. 1995 Nov;103 Suppl 8:205-8 [8741784.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2578-80 [9205057.001]
  • [Cites] J Pathol. 1998 Jun;185(2):130-8 [9713338.001]
  • [Cites] Annu Rev Biochem. 1998;67:753-91 [9759503.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Oncogene. 1999 Mar 18;18(11):2033-7 [10208426.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3098-103 [10340381.001]
  • [Cites] Mutat Res. 1999 Aug;406(2-4):71-7 [10479724.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2078-93 [15774796.001]
  • [Cites] Int J Cancer. 2005 Aug 10;116(1):62-8 [15761872.001]
  • [Cites] Am Surg. 2005 Apr;71(4):336-43 [15943410.001]
  • [Cites] Gut. 2005 Sep;54(9):1283-6 [15843421.001]
  • [Cites] Oncogene. 2005 Aug 29;24(37):5742-50 [16123807.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):29-40 [16289860.001]
  • [Cites] World J Gastroenterol. 2006 Jul 7;12(25):4033-7 [16810754.001]
  • [Cites] Int J Biol Sci. 2010;6(1):1-8 [20087440.001]
  • [Cites] Gastroenterology. 2010 Mar;138(3):969-80.e1-3 [19909744.001]
  • [Cites] Curr Opin Cell Biol. 2000 Apr;12(2):235-43 [10712925.001]
  • [Cites] N Engl J Med. 2000 May 4;342(18):1350-8 [10793168.001]
  • [Cites] Bioessays. 2001 Mar;23(3):223-32 [11223879.001]
  • [Cites] Ann Agric Environ Med. 2001;8(1):1-5 [11426918.001]
  • [Cites] Genome Biol. 2001;2(8):REVIEWS3010 [11532220.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1293-300 [11583957.001]
  • [Cites] J Cell Biol. 2002 Jan 21;156(2):299-313 [11790801.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2002 Sep;12(5):373-80 [12198585.001]
  • [Cites] Ann Intern Med. 2002 Oct 1;137(7):603-12 [12353948.001]
  • [Cites] Br Med Bull. 2002;64:1-25 [12421722.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):387-93 [14506738.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1597-604 [15014009.001]
  • [Cites] Exp Oncol. 2004 Jun;26(2):98-105 [15273660.001]
  • [Cites] Hum Mol Genet. 2004 Oct 1;13 Spec No 2:R177-85 [15358723.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Cancer Res. 1988 Dec 15;48(24 Pt 1):6999-7003 [3056609.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):339-46 [17390374.001]
  • [Cites] J Biol Chem. 2009 Jan 2;284(1):245-53 [19010789.001]
  • [Cites] Mutat Res. 2009 May 31;676(1-2):5-10 [19486858.001]
  • [Cites] Indian J Cancer. 2009 Jul-Sep;46(3):219-25 [19574674.001]
  • [Cites] Saudi J Gastroenterol. 2009 Oct-Dec;15(4):244-52 [19794270.001]
  • [Cites] Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(8):314-23 [19838011.001]
  • [Cites] Indian J Pathol Microbiol. 1990 Apr;33(2):118-23 [2391141.001]
  • (PMID = 20565773.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Transforming Growth Factor beta; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2927996
  •  go-up   go-down


59. Stelzer MK, Pitot HC, Liem A, Schweizer J, Mahoney C, Lambert PF: A mouse model for human anal cancer. Cancer Prev Res (Phila); 2010 Dec;3(12):1534-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mouse model for human anal cancer.
  • Human anal cancers are associated with high-risk human papillomaviruses (HPV) that cause other anogenital cancers and head and neck cancers.
  • As with other cancers, HPV16 is the most common high-risk HPV in anal cancers.
  • We describe the generation and characterization of a mouse model for human anal cancer.
  • This model makes use of K14E6 and K14E7 transgenic mice in which the HPV16 E6 and E7 genes are directed in their expression to stratified squamous epithelia.
  • Both E6 and E7 were found to be functionally expressed in the anal epithelia of K14E6/K14E7 transgenic mice.
  • To assess the susceptibility of these mice to anal cancer, mice were treated topically with dimethylbenz[a]anthracene (DMBA), a chemical carcinogen that is known to induce squamous cell carcinomas in other sites.
  • Histopathologic analyses confirmed that the HPV16 transgenic mice were increased in their susceptibility to anal cancers and precancerous lesions.
  • Biomarker analyses demonstrated that these mouse anal cancers exhibit properties that are similar to those observed in HPV-positive precursors to human anal cancer.
  • This is the first mouse model for investigating the contributions of viral and cellular factors in anal carcinogenesis, and should provide a platform for assessing new therapeutic modalities for treating and/or preventing this type of cancer.

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9094-103 [14645521.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4862-71 [12941807.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):263-75 [15137956.001]
  • [Cites] Cancer Res. 1982 Sep;42(9):3519-25 [6286109.001]
  • [Cites] J Pathol. 1990 Jun;161(2):99-103 [2199641.001]
  • [Cites] J Virol. 1996 Mar;70(3):1873-81 [8627712.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4350-4 [8633069.001]
  • [Cites] Nature. 1998 Nov 5;396(6706):84-8 [9817205.001]
  • [Cites] J Virol. 1999 Jul;73(7):5887-93 [10364340.001]
  • [Cites] Br J Surg. 2006 May;93(5):531-8 [16607677.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14152-7 [16959885.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1626-35 [17308103.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4605-19 [17510386.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6106-12 [17616666.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):313-27 [17936557.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2668-73 [17721920.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11585-93 [18089787.001]
  • [Cites] Mol Cancer. 2008;7:3 [18184435.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Mod Pathol. 2010 Jan;23(1):144-50 [19838162.001]
  • [Cites] J Am Acad Dermatol. 2010 Sep;63(3):490-8 [20006407.001]
  • [Cites] Br J Dermatol. 2010 Jun;162(6):1269-77 [20184584.001]
  • [Cites] Virology. 2000 Feb 15;267(2):141-50 [10662610.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8173-80 [14678972.001]
  • (PMID = 20947489.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098428-08; United States / NCI NIH HHS / CA / P01 CA022443-330006; United States / NCI NIH HHS / CA / R01 CA098428-09; United States / NCI NIH HHS / CA / U01 CA141583; United States / NCI NIH HHS / CA / P01 CA022443-320006; United States / NCI NIH HHS / CA / CA098428-08; United States / NCI NIH HHS / CA / CA022443-330006; United States / NCI NIH HHS / CA / CA141583-02; United States / NCI NIH HHS / CA / U01 CA141583-01; United States / NIDCR NIH HHS / DE / R01 DE017315-04; United States / NCI NIH HHS / CA / CA141583-01; United States / NCI NIH HHS / CA / CA022443-320006; United States / NIDCR NIH HHS / DE / R01 DE017315; United States / NIDCR NIH HHS / DE / R01 DE017315-05; United States / NCI NIH HHS / CA / CI T32 CA090217; United States / NCI NIH HHS / CA / T32 CA090217; United States / NCI NIH HHS / CA / U01 CA141583-02; United States / NCI NIH HHS / CA / P01 CA022443; United States / NCI NIH HHS / CA / R01 CA098428
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / E6 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / Repressor Proteins; 0 / oncogene protein E7, Human papillomavirus type 16; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  • [Other-IDs] NLM/ NIHMS211621; NLM/ PMC3006089
  •  go-up   go-down


60. Park K, Kim YS, Lee GY, Nam JO, Lee SK, Park RW, Kim SY, Kim IS, Byun Y: Antiangiogenic effect of bile acid acylated heparin derivative. Pharm Res; 2007 Jan;24(1):176-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Endothelial Cells. Extracellular Signal-Regulated MAP Kinases / metabolism. Fibroblast Growth Factors / analysis. Fibroblast Growth Factors / metabolism. Humans. Magnetic Resonance Spectroscopy. Mice. Mice, Inbred C57BL. Microtubules / drug effects. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / pathology. Phosphorylation. p38 Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HEPARIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thromb Res. 1978 May;12(5):773-82 [566964.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):3000-7 [7686447.001]
  • [Cites] Br J Cancer. 2002 Jun 5;86(11):1803-12 [12087470.001]
  • [Cites] Biochim Biophys Acta. 1985 May 30;845(2):196-203 [3995089.001]
  • [Cites] Pharmacol Rev. 2001 Mar;53(1):93-105 [11171940.001]
  • [Cites] Thromb Res. 1994 Jul 1;75(1):1-32 [8073404.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Sep 15;203(2):1339-47 [7522446.001]
  • [Cites] J Control Release. 2006 Sep 12;114(3):300-6 [16884806.001]
  • [Cites] J Clin Invest. 1973 Nov;52(11):2745-56 [4355998.001]
  • [Cites] Br J Cancer. 1984 Apr;49(4):405-13 [6201181.001]
  • [Cites] Langmuir. 2004 Dec 21;20(26):11726-31 [15595804.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2193-8 [11854515.001]
  • [Cites] Biochemistry. 1986 Sep 9;25(18):5322-8 [3768351.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4425-31 [7545541.001]
  • [Cites] News Physiol Sci. 2004 Feb;19:16-21 [14739398.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24653-60 [10816596.001]
  • [Cites] Angiogenesis. 1998;2(2):183-99 [14517473.001]
  • [Cites] Thromb Res. 1998 Nov 15;92(4):149-56 [9840023.001]
  • [Cites] Anal Biochem. 1980 Dec;109(2):466-73 [7224172.001]
  • [Cites] Biochemistry. 1994 Apr 5;33(13):3831-40 [8142385.001]
  • [Cites] Thromb Res. 1976 Feb;8(2):195-204 [1251350.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7163-9 [11156426.001]
  • [Cites] Biochemistry. 1994 Aug 30;33(34):10229-48 [7520751.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25902-9 [12704192.001]
  • [Cites] Nature. 2000 Oct 26;407(6807):1029-34 [11069186.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2743-50 [15087389.001]
  • [Cites] Glycobiology. 1996 Apr;6(3):355-66 [8724143.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3722-8 [12097281.001]
  • (PMID = 17109210.001).
  • [ISSN] 0724-8741
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Bile Acids and Salts; 62031-54-3 / Fibroblast Growth Factors; 9005-49-6 / Heparin; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


61. Tsao KC, Wu TL, Chang PY, Hong JH, Wu JT: Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers. J Clin Lab Anal; 2006;20(2):42-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 73,443 asymptomatic individuals were screened on a voluntary basis for cancer at Chang Gung Memorial Hospital in Taiwan using a panel of tumor markers, including alpha fetoprotein (AFP), CA 125, CA 15-3, CA 19-9, carcinoembryonic antigen (CEA), prostate specific antigen (PSA), chromogranin A (CgA), and squamous cell specific antigen (SCC).
  • Of the tumor markers monitored, elevated CA 19-9, CEA, and CA 125 were the most frequently detected in a variety of cancers.
  • Screening with multiple circulating tumor markers provides improved sensitivity for cancer detection in asymptomatic individuals before they reach the fatal advanced stage.
  • [MeSH-major] Asian Continental Ancestry Group. Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Mass Screening / methods
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. CA-19-9 Antigen / analysis. Cohort Studies. Female. Humans. Male. Middle Aged. Sensitivity and Specificity. Sex Distribution. Taiwan / epidemiology


62. El Badry AA, El-Fadle AA, El-Balshy AL: Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma. MedGenMed; 2007;9(3):3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma.
  • The present study was designed to clarify the role of TIMP-2 in nasopharyngeal carcinoma (NPC) patients and to evaluate its importance relative to clinicopathologic parameters.
  • Clinically, in accordance with TNM classification (T: tumor size, N: lymph node involvement, M: distant metastasis), 8 cases were diagnosed as stage II, 12 as stage III, and 10 cases as stage IV; however, pathologic typing with use of the World Health Organization (WHO) classification revealed the presence of 9 specimens of squamous cell carcinoma (WHO type 1), 6 cases of nonkeratinizing carcinoma (WHO type 2), and 15 cases of undifferentiated carcinoma (WHO type 3).
  • In addition, there was a significant positive correlation between TIMP-2 protein positivity and either the clinical staging or the histopathologic typing (P < .01) using Chi-square test (x(2)), suggesting that TIMP-2 can be used as a marker of the severity of NPC.Accordingly, we can assume that TIMP-2 may play a role in regional lymph node and/or distant metastasis and in progression of squamous cell carcinoma.
  • [MeSH-major] Carcinoma / chemistry. Carcinoma / enzymology. Nasopharyngeal Neoplasms / chemistry. Nasopharyngeal Neoplasms / enzymology. Tissue Inhibitor of Metalloproteinase-2 / analysis

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1999 Nov;189(3):300-8 [10547590.001]
  • [Cites] Am J Clin Pathol. 1993 Jan;99(1):18-23 [8422010.001]
  • [Cites] Adv Exp Med Biol. 2000;465:469-83 [10810650.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):215-8 [10901373.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):895-904 [10987249.001]
  • [Cites] Int J Oncol. 2000 Dec;17(6):1099-105 [11078794.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):44-50 [11241310.001]
  • [Cites] J Med Invest. 2001 Feb;48(1-2):31-43 [11286015.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):813-20 [11448356.001]
  • [Cites] Int J Colorectal Dis. 2001 Jun;16(3):133-40 [11459286.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3113-9 [11595703.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):26-34 [11796838.001]
  • [Cites] Isr Med Assoc J. 2002 Apr;4(4):247-51 [12001695.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7414-9 [12032297.001]
  • [Cites] Ai Zheng. 2002 Jan;21(1):91-4 [12500407.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Otolaryngol Head Neck Surg. 1983 Jun;91(3):255-62 [6308537.001]
  • [Cites] J Biol Chem. 1989 Oct 15;264(29):17374-8 [2793861.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):339-44 [7927938.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] Cancer Res. 1996 Apr 1;56(7):1654-9 [8603416.001]
  • [Cites] FEBS Lett. 1996 May 6;385(3):238-40 [8647259.001]
  • [Cites] Cancer Res. 1996 Jun 15;56(12):2707-10 [8665498.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):139-44 [8988738.001]
  • [Cites] Eur J Cell Biol. 1997 Oct;74(2):111-22 [9352216.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):439-44 [9398846.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):650-5 [9484825.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1359-66 [9529029.001]
  • [Cites] Clin Cancer Res. 1997 Sep;3(9):1623-8 [9815852.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):467-73 [9927064.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2C):1589-92 [10365151.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21491-4 [10419448.001]
  • [Cites] Head Neck. 1999 Oct;21(7):627-38 [10487950.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16485-90 [1653238.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2B):1085-91 [10810401.001]
  • (PMID = 18092010.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2
  • [Other-IDs] NLM/ PMC2100075
  •  go-up   go-down


63. Grose R, Fantl V, Werner S, Chioni AM, Jarosz M, Rudling R, Cross B, Hart IR, Dickson C: The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development. EMBO J; 2007 Mar 07;26(5):1268-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development.
  • Mice lacking epithelial Fgfr2b show great sensitivity to chemical carcinogenic insult, displaying several oncogenic ha-ras mutations with dramatic development of papillomas and squamous cell carcinomas.
  • Thus we describe a novel role of Fgfr2b and provide the first evidence of a tyrosine kinase receptor playing a tumor suppressive role in the skin.
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Epidermis / metabolism. Epidermis / pathology. Female. Hair / metabolism. Hair / pathology. Hair Follicle / metabolism. Hair Follicle / pathology. Immunohistochemistry. Keratin-5 / genetics. Keratin-5 / metabolism. Male. Mice. Mice, Knockout. Mutation. Papilloma / metabolism. Papilloma / pathology. Sebaceous Glands / metabolism. Sebaceous Glands / pathology

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunol Lett. 2001 Dec 3;79(3):215-9 [11600201.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11336-40 [11562460.001]
  • [Cites] Science. 2002 Apr 26;296(5568):747-9 [11976459.001]
  • [Cites] Development. 2003 Nov;130(21):5241-55 [12954714.001]
  • [Cites] Development. 2003 Nov;130(22):5493-501 [14530295.001]
  • [Cites] Curr Opin Biotechnol. 2003 Oct;14(5):533-7 [14580585.001]
  • [Cites] Oncogene. 1999 Dec 2;18(51):7234-43 [10602477.001]
  • [Cites] Development. 2000 Feb;127(3):483-92 [10631169.001]
  • [Cites] EMBO J. 2000 Aug 1;19(15):3990-4003 [10921880.001]
  • [Cites] Dev Biol. 2001 Mar 1;231(1):47-62 [11180951.001]
  • [Cites] Genome Biol. 2001;2(3):REVIEWS3005 [11276432.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3541-3 [11325814.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8784-90 [14695195.001]
  • [Cites] Eur J Cell Biol. 2004 Feb;83(1):3-11 [15085950.001]
  • [Cites] Genesis. 2004 May;39(1):52-7 [15124227.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):540-50 [15229479.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1771-8 [15105299.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):236-42 [15368475.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):405-6 [15385993.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Carcinogenesis. 1991 Oct;12(10):1875-81 [1934268.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6896-900 [1379725.001]
  • [Cites] EMBO J. 1993 Mar;12(3):973-86 [7681397.001]
  • [Cites] Science. 1994 Nov 4;266(5186):819-22 [7973639.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):145-54 [7604876.001]
  • [Cites] Genes Dev. 1996 Jan 15;10(2):165-75 [8566750.001]
  • [Cites] Oncogene. 1997 Jan 23;14(3):323-30 [9018118.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1642-55 [9501086.001]
  • [Cites] Genes Dev. 1998 Oct 15;12(20):3156-61 [9784490.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):138-41 [9916808.001]
  • [Cites] Oncogene. 2004 Dec 9;23(57):9201-11 [15516981.001]
  • [Cites] Oncogene. 2005 Feb 10;24(7):1290-5 [15592514.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):179-86 [15863033.001]
  • [Cites] Development. 2005 Jul;132(13):2981-90 [15930103.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):376-82 [16428475.001]
  • [Cites] J Cell Biochem. 2006 Mar 1;97(4):651-60 [16329135.001]
  • [Cites] Mol Cell Biol. 2006 May;26(10):3773-84 [16648473.001]
  • [Cites] Science. 2001 Oct 19;294(5542):605-9 [11567106.001]
  • (PMID = 17304214.001).
  • [ISSN] 0261-4189
  • [Journal-full-title] The EMBO journal
  • [ISO-abbreviation] EMBO J.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 076678; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-5; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 2
  • [Other-IDs] NLM/ PMC1817631; NLM/ UKMS1213
  •  go-up   go-down


64. Lukan N, Ströbel P, Willer A, Kripp M, Dinter D, Mai S, Hochhaus A, Hofheinz RD: Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology; 2009;77(5):293-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status.
  • BACKGROUND: No standard chemotherapy regimen can be defined for patients with metastatic squamous cell carcinoma of the anus due to the low incidence of this disease and the high cure rate of localized tumors.
  • Anal cancers universally express the epidermal growth factor receptor (EGFR) and KRAS mutations have not been reported in anal cancer thus far.
  • METHODS: We report on 7 patients with metastatic anal cancer treated with cetuximab - a chimeric antibody against EGFR - on a compassionate use basis along with the results of KRAS mutational analysis.
  • CONCLUSION: Cetuximab-based treatment appears to be a valuable treatment option for patients with metastatic KRAS wild-type anal cancer after failure of or as an alternative to cisplatin/5-fluorouracil-based therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Mutation. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / antagonists & inhibitors. ras Proteins / genetics

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19923868.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins; PQX0D8J21J / Cetuximab
  •  go-up   go-down


65. Hauerstock D, Ennis RD, Grossbard M, Evans A: Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer. Clin Colorectal Cancer; 2010 Oct;9(4):238-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer.
  • PURPOSE: The purpose of this retrospective study is to determine the results and the toxicity of concurrent chemoradiation for squamous cell carcinoma of the anal canal in HIV-positive patients treated at a single institution.
  • PATIENTS AND METHODS: HIV-positive patients with squamous cell carcinoma of the canal treated at Continuum Cancer Centers-affiliated hospitals were identified from tumor registries.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Infections / complications. Radiotherapy, Conformal


66. Konstantinopoulos PA, Pantanowitz L, Schlecht HP, Dezube BJ: Images in HIV/AIDS. HIV-associated squamous cell carcinoma of the anus. AIDS Read; 2006 Jun;16(6):301-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Images in HIV/AIDS. HIV-associated squamous cell carcinoma of the anus.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / virology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. HIV Infections / complications


67. Jiménez W, Paszat L, Kupets R, Wilton A, Tinmouth J: Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. Gynecol Oncol; 2009 Sep;114(3):395-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario.
  • OBJECTIVE: The oncogenic HPV subtypes responsible for gynecologic malignancies have also been implicated in the development of squamous cell cancer of the anus (SCAC).
  • The aim of this study was determine whether women diagnosed with anal cancer are more likely to have a history of HPV-related gynecological cancer as compared to a matched control group.
  • The exposure of interest was previous HPV-related gynecologic cancer, specifically cervical cancer, vulvar cancer and vaginal cancer.
  • Previous HPV-related gynecological cancer (cervical, vaginal or vulvar cancer) was significantly associated with SCAC (OR: 10.5, 95% C.I.: 3.6 to 30.3).
  • The median time between the diagnosis of anal cancer and previous cervical cancer was 20 years.
  • CONCLUSIONS: Previous HPV-related gynecological cancers are strongly associated with anal cancer and may occur decades before the anal cancer.
  • [MeSH-major] Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology. Genital Neoplasms, Female / epidemiology. Neoplasms, Multiple Primary / epidemiology. Papillomavirus Infections / epidemiology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19501390.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


68. Greenberg R, Greenwald B, Roth JS, Ioffe O, Cross R: Squamous dysplasia of the rectum in a patient with ulcerative colitis treated with 6-mercaptopurine. Dig Dis Sci; 2008 Mar;53(3):760-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous dysplasia of the rectum in a patient with ulcerative colitis treated with 6-mercaptopurine.
  • Human papilloma virus (HPV) has been found to be a precursor and risk factor for both cervical and anal dysplasia.
  • Cervical dysplasia, which is the precursor to carcinoma, is associated with immunosuppression from a variety of causes; reports of anal dysplasia associated with immune suppression exist as well.
  • We report a case of a 50-year-old woman with refractory ulcerative colitis chronically treated with 6-mercaptopurine that developed severe squamous dysplasia of the rectum.
  • This case highlights the importance of immune suppression in the development of dysplasia of the anus/cervix secondary to HPV infection.
  • [MeSH-major] 6-Mercaptopurine / adverse effects. Colitis, Ulcerative / drug therapy. Immunosuppressive Agents / adverse effects. Neoplasms, Squamous Cell / chemically induced. Rectal Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):303-15 [16507827.001]
  • [Cites] Transplant Proc. 1973 Mar;5(1):943-7 [4735211.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • [Cites] Transplant Proc. 1972 Dec;4(4):719-32 [4345730.001]
  • [Cites] Obstet Gynecol. 1994 Oct;84(4):591-7 [8090399.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] Acta Obstet Gynecol Scand. 1978;57(1):73-8 [341640.001]
  • [Cites] AIDS. 1995 Nov;9(11):1255-62 [8561979.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1095-101 [16586444.001]
  • [Cites] Scott Med J. 1980 Oct;25(4):275-7 [7010590.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Surg Oncol. 1995 May;59(1):48-55 [7745978.001]
  • [Cites] Can J Gastroenterol. 2007 Jan;21(1):47-50 [17225882.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1666-9 [8348498.001]
  • [Cites] Gut. 2005 Feb;54(2):237-41 [15647188.001]
  • [Cites] Gastroenterology. 2004 May;126(6):1504-17 [15168363.001]
  • [Cites] Cleve Clin Q. 1985 Summer;52(2):257-61 [4028428.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):320-6 [9525432.001]
  • [Cites] J Obstet Gynaecol. 2005 Apr;25(3):286-8 [16147738.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):341-6 [11289278.001]
  • [Cites] Am J Epidemiol. 1990 Jun;131(6):945-57; discussion 958-60 [2188500.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):611-6 [3524788.001]
  • [Cites] Gastroenterology. 2006 Mar;130(3):940-87 [16530532.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2005 Aug 1;121(2):226-32 [16054967.001]
  • (PMID = 17717741.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; E7WED276I5 / 6-Mercaptopurine
  •  go-up   go-down


69. Martellucci J, Naldini G, Colosimo C, Cionini L, Rossi M: Accuracy of endoanal ultrasound in the follow-up assessment for squamous cell carcinoma of the anal canal treated with radiochemotherapy. Surg Endosc; 2009 May;23(5):1054-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of endoanal ultrasound in the follow-up assessment for squamous cell carcinoma of the anal canal treated with radiochemotherapy.
  • BACKGROUND: Radiochemotherapy has largely replaced surgery in the treatment for squamous cell cancer of the anal canal.
  • Transanal ultrasonography is well documented as an important investigation method in the management of anal carcinoma.
  • METHODS: The study enrolled 16 consecutive patients with biopsy-proven squamous carcinoma of the anal canal between 2003 and 2006.
  • CONCLUSIONS: Endoanal ultrasound is a safe and effective method for evaluating and following anal cancer before and after treatment.
  • Experience and evaluation during the period of the ultrasonographic abnormalities could give a clear idea concerning the evolution of the anal tumors treated with radiochemotherapy.
  • [MeSH-major] Anus Neoplasms / diagnostic imaging. Carcinoma, Squamous Cell / diagnostic imaging. Endosonography

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2002 Jul;43(1):77-92 [12098609.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):16-22 [11786758.001]
  • [Cites] Endoscopy. 1999 Jun;31(5):359-64 [10433044.001]
  • [Cites] Surg Clin North Am. 2004 Aug;84(4):1127-49, vii [15261756.001]
  • [Cites] Surg Endosc. 1994 Oct;8(10 ):1186-9 [7809802.001]
  • [Cites] Endoscopy. 2001 Mar;33(3):231-6 [11293755.001]
  • [Cites] Dis Colon Rectum. 2004 Jun;47(6):839-42 [15085443.001]
  • [Cites] Eur J Radiol. 2003 Aug;47(2):142-8 [12880995.001]
  • (PMID = 18813993.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


70. Bendel P, Wittig A, Basilico F, Mauri PL, Sauerwein W: Metabolism of borono-phenylalanine-fructose complex (BPA-fr) and borocaptate sodium (BSH) in cancer patients--results from EORTC trial 11001. J Pharm Biomed Anal; 2010 Jan 5;51(1):284-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolism of borono-phenylalanine-fructose complex (BPA-fr) and borocaptate sodium (BSH) in cancer patients--results from EORTC trial 11001.
  • These observations were previously reported for cultured cells and animal models, and are confirmed here in human cancer patients.
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / therapy. Clinical Trials as Topic. Fructose / chemistry. Head and Neck Neoplasms / therapy. Humans. Magnetic Resonance Spectroscopy / methods. Time Factors

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19735988.001).
  • [ISSN] 1873-264X
  • [Journal-full-title] Journal of pharmaceutical and biomedical analysis
  • [ISO-abbreviation] J Pharm Biomed Anal
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Borohydrides; 0 / Boron Compounds; 0 / Sulfhydryl Compounds; 12294-22-3 / mercaptoundecahydrododecaborate; 30237-26-4 / Fructose; 47E5O17Y3R / Phenylalanine; UID84303EL / 4-boronophenylalanine
  •  go-up   go-down


71. Richard SD, Krivak TC, Beriwal S, Zorn KK: Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1132-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab.
  • Recurrent vulvar carcinoma with metastasis has few effective treatment options, which are mainly directed toward palliation of symptoms.
  • A 70-year-old woman was originally treated in 1999 for vulvar squamous cell carcinoma (SCC) with radical vulvectomy and bilateral inguinofemoral groin dissection.
  • Despite radical surgical resection with an anal perineal resection, she presented 2 months later with widely metastatic disease.
  • Few treatment options exist for recurrent metastatic vulvar carcinoma.
  • The partial response experienced in our patient suggests its potential use in women with recurrent or metastatic vulvar carcinoma.

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021214.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


72. Arikawa S, Uchida M, Ogoh E, Uozumi J, Yoshida S, Watanabe Y, Kaida H, Ishibashi N, Shirouzu K, Hayabuchi N: [Drug eruption (erythema multiforme type) following chemoradiotherapy with mitomycin C and 5-fluorouracil administration for squamous cell carcinoma of the anal canal]. Gan To Kagaku Ryoho; 2010 Apr;37(4):727-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Drug eruption (erythema multiforme type) following chemoradiotherapy with mitomycin C and 5-fluorouracil administration for squamous cell carcinoma of the anal canal].
  • We report a case of drug eruption (erythema multiforme type) in a 54-year-old woman, following concurrent chemoradiotherapy for squamous cell carcinoma of the anal canal.
  • Although we could not provide sufficient chemotherapy and radiation therapy due to severe side effects, squamous cell carcinoma of the anal canal responded extremely well with a marked decrease in complete response.
  • Concurrent chemoradiotherapy is safe and effective for squamous cell carcinoma of the anal canal, but care is required to prevent drug eruption during treatment.
  • [MeSH-major] Anal Canal / pathology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Squamous Cell / drug therapy. Erythema Multiforme / chemically induced. Fluorouracil / adverse effects. Mitomycin / therapeutic use. Rectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Erythema Multiforme.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414036.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Steroids; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


73. Yang K, Li Z, Cao Y, Yu X, Mei J: Effect of peptide-conjugated near-infrared fluorescent quantum dots (NIRF-QDs) on the invasion and metastasis of human tongue squamous cell carcinoma cell line Tca8113 in vitro. Int J Mol Sci; 2009 Oct;10(10):4418-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of peptide-conjugated near-infrared fluorescent quantum dots (NIRF-QDs) on the invasion and metastasis of human tongue squamous cell carcinoma cell line Tca8113 in vitro.
  • In this study we investigated the effect of near-infrared fluorescent quantum dots (NIRF-QDs, QTracker) on the proliferation, adherence, invasion and chemotaxis of human tongue squamous cell carcinoma cell line Tca8113 in vitro.
  • Cell proliferation and colony formation rate were determined by using a hemocytometer and culture plate.
  • A transwell chamber assay was used to determine the cell invasion, adherence and chemotaxis.
  • [MeSH-minor] Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Line, Tumor. Cell Movement / drug effects. Cell Proliferation / drug effects. Humans. Spectroscopy, Near-Infrared. Tongue Neoplasms / metabolism. Tongue Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2003 Jan;21(1):47-51 [12459736.001]
  • [Cites] Nat Biotechnol. 2003 Jan;21(1):41-6 [12459735.001]
  • [Cites] Nat Biotechnol. 2004 Jan;22(1):47-52 [14704706.001]
  • [Cites] Nat Biotechnol. 2004 Aug;22(8):969-76 [15258594.001]
  • [Cites] Nat Med. 2004 Sep;10(9):993-8 [15334072.001]
  • [Cites] Science. 2005 Jan 28;307(5709):538-44 [15681376.001]
  • [Cites] Nat Mater. 2005 Jun;4(6):435-46 [15928695.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11631-8 [16357174.001]
  • [Cites] Nano Lett. 2006 Apr;6(4):669-76 [16608262.001]
  • [Cites] Methods Mol Biol. 2007;374:147-59 [17237537.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1138-44 [17283148.001]
  • [Cites] J Am Chem Soc. 2007 Nov 28;129(47):14759-66 [17983227.001]
  • [Cites] BMC Biotechnol. 2007;7:67 [17925032.001]
  • [Cites] Bioconjug Chem. 2008 Feb;19(2):421-7 [18081241.001]
  • [Cites] Langmuir. 2008 Oct 21;24(20):11866-71 [18823093.001]
  • [Cites] Nat Biotechnol. 2001 Jul;19(7):631-5 [11433273.001]
  • [Cites] Science. 2002 Nov 29;298(5599):1759-62 [12459582.001]
  • [Cites] Anal Biochem. 2004 Jan 1;324(1):60-7 [14654046.001]
  • (PMID = 20057952.001).
  • [ISSN] 1422-0067
  • [Journal-full-title] International journal of molecular sciences
  • [ISO-abbreviation] Int J Mol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Peptides
  • [Other-IDs] NLM/ PMC2790115
  • [Keywords] NOTNLM ; adherence / chemotaxis / invasion / near-infrared fluorescence / peptide / quantum dots / tumor
  • [General-notes] NLM/ Original DateCompleted: 20100628
  •  go-up   go-down


74. Du Y, Li Z, Li L, Chen ZG, Sun SY, Chen P, Shin DM, Khuri FR, Fu H: Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells. J Recept Signal Transduct Res; 2009;29(3-4):182-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells.
  • Targeting dysregulated signaling pathways in tumors has led to the development of a novel class of signal transduction inhibitors, including inhibitors of the epidermal growth factor (EGF) receptor (EGFR).
  • Here we report the application of a label-free optical biosensor to reveal the rapid response of cancer cells to EGF, expressed as a dynamic mass redistribution (DMR) signal.
  • In response to EGF, squamous cell carcinoma of the head and neck cells exhibited a rapid rise in DMR signal, whereas lung adenocarcinoma cells showed a biphasic DMR profile, suggesting a cell type-dependent DMR response.
  • The assay can also be used for cell-based high-throughput screening of EGF pathway inhibitors, as demonstrated by its robust performance in a 384-well plate format (Z' > 0.5).
  • [MeSH-minor] Antineoplastic Agents / isolation & purification. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Epidermal Growth Factor / pharmacology. Erlotinib Hydrochloride. Humans. Protein Kinase Inhibitors / pharmacology. Quinazolines / pharmacology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2005 Aug 1;579(19):4175-80 [16038906.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):991-1002 [14967461.001]
  • [Cites] Med Res Rev. 2006 Sep;26(5):569-94 [16788977.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2005;1:666-9 [17282270.001]
  • [Cites] Gene. 2006 Jan 17;366(1):2-16 [16377102.001]
  • [Cites] Cancer. 2008 Jul 1;113(1):97-107 [18473353.001]
  • [Cites] Adv Cancer Res. 1998;74:49-139 [9561267.001]
  • [Cites] Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):15-25 [16736979.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3159-67 [10880430.001]
  • [Cites] J Biomol Screen. 1999;4(2):67-73 [10838414.001]
  • [Cites] Cancer Control. 2007 Jul;14(3):295-304 [17615536.001]
  • [Cites] Oncology (Williston Park). 2006 Feb;20(2):153-61; discussion 162, 166, 169 passim [16562649.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Anal Chem. 2005 Sep 1;77(17):5720-5 [16131087.001]
  • [Cites] Assay Drug Dev Technol. 2006 Oct;4(5):583-95 [17115929.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(1):35-45 [17098420.001]
  • [Cites] Cancer Res. 1996 Aug 1;56(15):3540-5 [8758924.001]
  • [Cites] Biophys J. 2006 Sep 1;91(5):1925-40 [16766609.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2004;44:195-217 [14744244.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] J Biol Chem. 1988 Mar 5;263(7):3496-500 [2830286.001]
  • [Cites] Annu Rev Biochem. 1998;67:481-507 [9759495.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4838-48 [9354447.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7350-6 [12499279.001]
  • [Cites] Biotechnol J. 2008 Apr;3(4):484-95 [18412175.001]
  • [Cites] Clin Lung Cancer. 2007 Feb;8 Suppl 2:S79-85 [17382029.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4249s-4253s [15217968.001]
  • [Cites] Oncol Rep. 2008 Jan;19(1):65-71 [18097577.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):217-23 [19038731.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5749-54 [12384534.001]
  • [Cites] ScientificWorldJournal. 2008;8:909-19 [18836658.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 3;90(11):824-32 [9625170.001]
  • (PMID = 19604037.001).
  • [ISSN] 1532-4281
  • [Journal-full-title] Journal of receptor and signal transduction research
  • [ISO-abbreviation] J. Recept. Signal Transduct. Res.
  • [Language] eng
  • [Grant] United States / NHGRI NIH HHS / HG / U54 HG003918; United States / NCI NIH HHS / CA / 5 P50 CA128613; United States / NCI NIH HHS / CA / P01 CA116676-04; United States / NHGRI NIH HHS / HG / 5U54 HG003918; United States / NHGRI NIH HHS / HG / U54 HG003918-03; United States / NCI NIH HHS / CA / P01 CA116676; United States / NCI NIH HHS / CA / T32 CA160040; United States / NCI NIH HHS / CA / P50 CA128613-03; United States / NCI NIH HHS / CA / P50 CA128613
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 62229-50-9 / Epidermal Growth Factor; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ NIHMS142951; NLM/ PMC3746742
  •  go-up   go-down


75. Mäusbacher N, Schreiber TB, Daub H: Glycoprotein capture and quantitative phosphoproteomics indicate coordinated regulation of cell migration upon lysophosphatidic acid stimulation. Mol Cell Proteomics; 2010 Nov;9(11):2337-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glycoprotein capture and quantitative phosphoproteomics indicate coordinated regulation of cell migration upon lysophosphatidic acid stimulation.
  • The underlying signaling mechanisms are still incompletely understood, including those that operate at the plasma membrane to modulate cell-cell and cell-matrix interactions in LPA-promoted cell migration.
  • To explore LPA-evoked phosphoregulation with a focus on cell surface proteins, we combined glycoproteome enrichment by immobilized lectins with SILAC-based quantitative phosphoproteomics.
  • We performed biological replicate analyses in SCC-9 squamous cell carcinoma cells and repeatedly quantified the effect of 1.5- and 5-min LPA treatment on more than 700 distinct phosphorylations in lectin-purified proteins.
  • We detected many regulated phosphorylation events on various types of plasma membrane proteins such as cell adhesion molecules constituting adherens junctions, desmosomes, and hemidesmosomes.
  • Several of these LPA-regulated phosphorylation sites have been characterized in a biological context other than G protein-coupled receptor signaling, and the transfer of this functional information suggests coordinated and multifactorial cell adhesion control in LPA-induced cell migration.
  • Additionally, we identified LPA-mediated activation loop phosphorylation of the serine/threonine kinase Wnk1 and verified a role of Wnk1 for LPA-induced cell migration in knock-down experiments.
  • In conclusion, the glycoproteome phosphoproteomics strategy described here sheds light on incompletely understood mechanisms in LPA-induced cell migratory behavior.
  • [MeSH-major] Cell Movement / drug effects. Glycoproteins / chemistry. Lysophospholipids / pharmacology. Phosphoproteins / chemistry. Proteomics / methods
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Line, Tumor. Computational Biology. Humans. Molecular Sequence Data. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism. Receptors, G-Protein-Coupled / metabolism. Receptors, Lysophosphatidic Acid / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):582-91 [12894246.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1203-8 [14641026.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):991-9 [14647423.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23038-44 [15039423.001]
  • [Cites] Anal Chem. 2004 Jul 1;76(13):3590-8 [15228329.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):3935-43 [15253627.001]
  • [Cites] J Cell Biochem. 2004 Aug 1;92(5):949-66 [15258918.001]
  • [Cites] Mol Cell. 2004 Sep 24;15(6):937-49 [15383283.001]
  • [Cites] Anal Biochem. 1984 Apr;138(1):141-3 [6731838.001]
  • [Cites] J Biol Chem. 1990 Aug 5;265(22):12820-7 [2115882.001]
  • [Cites] J Biol Chem. 1991 May 5;266(13):8355-62 [2022651.001]
  • [Cites] J Biol Chem. 1992 Apr 25;267(12):8672-8 [1314835.001]
  • [Cites] Cell. 1992 Aug 7;70(3):389-99 [1643657.001]
  • [Cites] J Cell Physiol. 1994 Jan;158(1):151-9 [7505275.001]
  • [Cites] EMBO J. 1997 Dec 1;16(23):7032-44 [9384582.001]
  • [Cites] Science. 1998 Jun 26;280(5372):2112-4 [9641916.001]
  • [Cites] Science. 1998 Nov 13;282(5392):1281-4 [9812885.001]
  • [Cites] Science. 1998 Nov 13;282(5392):1279-80 [9867633.001]
  • [Cites] Biochem J. 1999 Mar 1;338 ( Pt 2):471-8 [10024525.001]
  • [Cites] J Biol Chem. 1999 Jul 16;274(29):20206-14 [10400637.001]
  • [Cites] Thromb Haemost. 2005 Jan;93(1):27-34 [15630487.001]
  • [Cites] Oncogene. 2005 Mar 24;24(13):2218-28 [15688026.001]
  • [Cites] Mol Cell Proteomics. 2005 Jul;4(7):873-86 [15858219.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26653-8 [15883153.001]
  • [Cites] Nat Biotechnol. 2005 Nov;23(11):1391-8 [16273072.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D412-6 [18940858.001]
  • [Cites] Proteomics. 2008 Dec;8(23-24):5108-18 [19016532.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):884-8 [10622253.001]
  • [Cites] J Biol Chem. 2000 Jun 2;275(22):16795-801 [10828064.001]
  • [Cites] Mol Biol Cell. 2001 Feb;12(2):351-65 [11179420.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7108-13 [11383510.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(7):2375-87 [11884620.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):12838-45 [11823465.001]
  • [Cites] Mol Biol Cell. 2002 Jun;13(6):2031-44 [12058067.001]
  • [Cites] Mol Cell Proteomics. 2002 May;1(5):376-86 [12118079.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):29431-6 [12058027.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6329-36 [12414665.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48456-62 [12374799.001]
  • [Cites] Biotechniques. 2003 Feb;34(2):374-8 [12613259.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] EMBO J. 2003 May 15;22(10):2411-21 [12743035.001]
  • [Cites] Biochemistry. 2003 Aug 5;42(30):9195-204 [12885254.001]
  • [Cites] Mol Cell Proteomics. 2005 Dec;4(12):2010-21 [16249172.001]
  • [Cites] J Biol Chem. 2005 Dec 30;280(52):42685-93 [16263722.001]
  • [Cites] Mol Cell Proteomics. 2006 Feb;5(2):226-33 [16263699.001]
  • [Cites] Mol Cell Proteomics. 2006 May;5(5):923-34 [16452088.001]
  • [Cites] J Proteome Res. 2006 Jun;5(6):1493-503 [16740002.001]
  • [Cites] Mol Cell Biol. 2006 Jul;26(14):5481-96 [16809781.001]
  • [Cites] Nat Protoc. 2009;4(1):44-57 [19131956.001]
  • [Cites] Immunity. 2009 Jan 16;30(1):143-54 [19144319.001]
  • [Cites] Mol Cell Proteomics. 2009 Feb;8(2):287-301 [18923192.001]
  • [Cites] Cell. 2009 Aug 7;138(3):525-36 [19665974.001]
  • [Cites] Curr Opin Chem Biol. 2009 Oct;13(4):414-20 [19620020.001]
  • [Cites] Science. 2009 Sep 25;325(5948):1682-6 [19779198.001]
  • [Cites] Mol Cell. 2010 Feb 26;37(4):551-66 [20188673.001]
  • [Cites] Nat Rev Mol Cell Biol. 2010 Jun;11(6):427-39 [20461098.001]
  • [Cites] Mol Cell Proteomics. 2010 Jun;9(6):1047-62 [20071362.001]
  • [Cites] Cell. 2006 Nov 3;127(3):635-48 [17081983.001]
  • [Cites] J Neurochem. 2006 Nov;99(4):1114-21 [17018027.001]
  • [Cites] Oncogene. 2006 Nov 30;25(56):7381-90 [16785992.001]
  • [Cites] Oncogene. 2006 Nov 30;25(56):7401-10 [16785995.001]
  • [Cites] J Cell Biol. 2007 Jan 1;176(1):89-100 [17190791.001]
  • [Cites] Nat Biotechnol. 2007 Mar;25(3):285-6 [17344875.001]
  • [Cites] Nat Protoc. 2006;1(6):2856-60 [17406544.001]
  • [Cites] J Biol Chem. 2007 Apr 13;282(15):11221-9 [17287208.001]
  • [Cites] Methods Mol Biol. 2007;359:37-52 [17484109.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2007 Jul;16(4):365-72 [17565280.001]
  • [Cites] Anal Chem. 2007 Aug 1;79(15):5826-37 [17591751.001]
  • [Cites] Nat Protoc. 2007;2(8):1896-906 [17703201.001]
  • [Cites] Proteomics. 2007 Aug;7(16):2751-68 [17703509.001]
  • [Cites] Mol Biol Cell. 2007 Sep;18(9):3512-22 [17615294.001]
  • [Cites] J Cell Physiol. 2007 Dec;213(3):589-602 [17786953.001]
  • [Cites] Semin Cancer Biol. 2008 Feb;18(1):65-76 [18023204.001]
  • [Cites] Cancer Immunol Immunother. 2008 Sep;57(9):1347-55 [18297283.001]
  • [Cites] Methods Mol Biol. 2008;484:263-76 [18592185.001]
  • [Cites] J Proteome Res. 2008 Aug;7(8):3304-13 [18578522.001]
  • [Cites] Mol Cell. 2008 Aug 8;31(3):438-48 [18691976.001]
  • [Cites] Curr Opin Cell Biol. 2008 Oct;20(5):589-96 [18583123.001]
  • [Cites] Mol Cell Proteomics. 2008 Sep;7(9):1763-77 [18515860.001]
  • [Cites] J Cell Sci. 2008 Oct 15;121(Pt 20):3293-304 [18843116.001]
  • [Cites] Nat Biotechnol. 2008 Dec;26(12):1367-72 [19029910.001]
  • (PMID = 20639409.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Lysophospholipids; 0 / Phosphoproteins; 0 / Receptors, G-Protein-Coupled; 0 / Receptors, Lysophosphatidic Acid; 22002-87-5 / lysophosphatidic acid; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2984229
  •  go-up   go-down


76. Sato E, Fujimoto J, Toyoki H, Sakaguchi H, Alam SM, Jahan I, Tamaya T: Expression of IP-10 related to angiogenesis in uterine cervical cancers. Br J Cancer; 2007 Jun 4;96(11):1735-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. Chemokines, CXC / genetics. Neovascularization, Pathologic / genetics. Uterine Cervical Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Cancer Res. 1985;43:175-203 [2581424.001]
  • [Cites] Cancer. 1982 Sep 1;50(5):932-8 [6807530.001]
  • [Cites] Biochem Biophys Res Commun. 1995 May 5;210(1):51-7 [7537965.001]
  • [Cites] Blood. 1996 May 1;87(9):3877-82 [8611715.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):884-8 [8611421.001]
  • [Cites] Invasion Metastasis. 1995;15(5-6):203-10 [8765195.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13791-6 [8943014.001]
  • [Cites] Cancer Lett. 1997 Jan 1;111(1-2):21-6 [9022124.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2632-5 [10825134.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3662-5 [10910083.001]
  • [Cites] Cancer Immunol Immunother. 2001 Jan;49(11):587-92 [11225989.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):313-6 [11487257.001]
  • [Cites] Int J Cancer. 2002 May 1;99(1):149-53 [11948506.001]
  • [Cites] Ann Oncol. 2002 Mar;13(3):430-4 [11996475.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):963-9 [9064356.001]
  • [Cites] J Immunol. 1997 Aug 1;159(3):1437-43 [9233641.001]
  • [Cites] Blood. 1997 Aug 1;90(3):909-28 [9242519.001]
  • [Cites] Eur J Gynaecol Oncol. 1997;18(5):349-52 [9378151.001]
  • [Cites] Cancer Lett. 1998 Apr 10;126(1):83-8 [9563652.001]
  • [Cites] Cancer Lett. 1998 Aug 14;130(1-2):115-20 [9751263.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2528-33 [9874459.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1249-54 [10098767.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):827-33 [10360662.001]
  • [Cites] Cancer Lett. 1998 Dec 11;134(1):15-22 [10381125.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3041-4 [10397240.001]
  • [Cites] J Immunol. 2005 Aug 15;175(4):2721-9 [16081850.001]
  • [Cites] J Immunol. 2006 Mar 1;176(5):3098-107 [16493069.001]
  • [Cites] Circ Res. 2006 Mar 17;98(5):617-25 [16484616.001]
  • [Cites] Exp Eye Res. 2006 Aug;83(2):374-9 [16674942.001]
  • [Cites] Ann Oncol. 2002 Oct;13(10):1598-604 [12377648.001]
  • [Cites] J Exp Med. 2003 Jun 2;197(11):1537-49 [12782716.001]
  • [Cites] Am J Reprod Immunol. 2003 Jul;50(1):60-5 [14506929.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):466-9 [15226772.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • (PMID = 17505511.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCL10 protein, human; 0 / Chemokine CXCL10; 0 / Chemokines, CXC; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2359925
  •  go-up   go-down


77. Scarpini C, White V, Muralidhar B, Patterson A, Hickey N, Singh N, Mullerat J, Winslet M, Davies RJ, Phillips ML, Stacey P, Laskey RA, Miller R, Nathan M, Coleman N: Improved screening for anal neoplasia by immunocytochemical detection of minichromosome maintenance proteins. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2855-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved screening for anal neoplasia by immunocytochemical detection of minichromosome maintenance proteins.
  • PURPOSE: Early detection of anal intraepithelial neoplasia (AIN) and anal squamous cell carcinoma (SCC) by screening will improve clinical outcome.
  • Assessment of anal cytology samples using routine Papanicolaou testing suffers from shortcomings in sensitivity and/or specificity, suggesting that screening tests based on biomarkers may be of value.
  • We tested the suitability in this context of minichromosome maintenance (MCM) proteins, accurate markers of the deregulated cell cycle entry that characterizes malignancy and premalignancy.
  • EXPERIMENTAL DESIGN: We undertook an initial immunohistochemical study of 54 anal tissue samples and validated our findings using an independent prospective cohort study of 235 anal cytology samples from 144 subjects.
  • RESULTS: In the progression from normal anal epithelium through AIN to SCC, there was increasing expression of MCM2 and MCM5, including in the superficial epithelial third, the source of the majority of cells collected by anal swab.
  • MCM LIs in the superficial layers were significantly greater than LIs for Ki67, an alternative marker of cell cycle entry (P<0.0001).
  • By immunocytochemistry using a mixture of anti-MCM2 and anti-MCM5 antibodies, immunopositive cells were readily identified in anal cytology samples, even at low magnification.
  • CONCLUSIONS: MCMs are promising biomarkers for improving detection of AIN and SCC in anal cytology samples.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cell Cycle Proteins / metabolism. Nuclear Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18843031.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105359875; United Kingdom / Medical Research Council / / MC/ U105359878; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / MCM5 protein, human; 0 / Nuclear Proteins; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


78. Huang Y, Sen T, Nagpal J, Upadhyay S, Trink B, Ratovitski E, Sidransky D: ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle; 2008 Sep 15;7(18):2846-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):305-11 [17224650.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):300-4 [17264676.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):274-85 [17264681.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):240-5 [17297296.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):246-54 [17297308.001]
  • [Cites] Cell Cycle. 2007 Apr 15;6(8):931-42 [17457059.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1370-80 [17446929.001]
  • [Cites] Cell Cycle. 2007 May 2;6(9):1062-71 [17426453.001]
  • [Cites] Cell Cycle. 2006 Nov 1;5(21):2489-94 [17106255.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6325-32 [17616691.001]
  • [Cites] Cell Cycle. 2007 Aug 1;6(15):1831-6 [17671427.001]
  • [Cites] Mol Cell Biol. 2000 May;20(9):3224-33 [10757806.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5462-7 [10805802.001]
  • [Cites] Oncogene. 2000 Jun 22;19(27):3126-30 [10871867.001]
  • [Cites] J Biol Chem. 2000 Jul 28;275(30):22719-27 [10801797.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4016-20 [10945600.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1817-22 [11172034.001]
  • [Cites] Nat Biotechnol. 2001 Apr;19(4):375-8 [11283598.001]
  • [Cites] Oncogene. 2001 Apr 5;20(15):1803-15 [11313928.001]
  • [Cites] Eur J Biochem. 2001 May;268(10):2764-72 [11358490.001]
  • [Cites] Mol Pharmacol. 2001 Sep;60(3):405-15 [11502869.001]
  • [Cites] Apoptosis. 2007 Oct;12(10):1847-55 [17636382.001]
  • [Cites] Cell Cycle. 2007 Oct 1;6(19):2339-40 [17914283.001]
  • [Cites] Cell Cycle. 2007 Dec 15;6(24):3114-31 [18075315.001]
  • [Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]
  • [Cites] Cell Cycle. 2008 May 1;7(9):1231-7 [18418053.001]
  • [Cites] Cell Cycle. 2008 May 15;7(10):1353-9 [18418074.001]
  • [Cites] Cell Cycle. 2004 Jan;3(1):80-9 [14657672.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51408-14 [14555649.001]
  • [Cites] Oncogene. 2004 Mar 11;23(10):1829-37 [14647429.001]
  • [Cites] Annu Rev Biochem. 2004;73:39-85 [15189136.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):793-805 [15510160.001]
  • [Cites] Methods Enzymol. 1991;200:3-37 [1835513.001]
  • [Cites] J Biol Chem. 1995 Sep 8;270(36):21396-403 [7545671.001]
  • [Cites] Eur J Biochem. 1997 Jan 15;243(1-2):518-26 [9030780.001]
  • [Cites] Eur J Biochem. 1997 Jan 15;243(1-2):527-36 [9030781.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1674-7 [9733514.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2781-6 [10383130.001]
  • [Cites] J Virol. 2004 Dec;78(24):13501-11 [15564461.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9152-9 [15604286.001]
  • [Cites] Cell Cycle. 2004 Oct;3(10):1285-95 [15467455.001]
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1099-105 [10594758.001]
  • [Cites] J Biol Chem. 1999 Dec 31;274(53):37538-43 [10608806.001]
  • [Cites] Electrophoresis. 1999 Dec;20(18):3551-67 [10612281.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7803-10 [10713094.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):31819-24 [11431470.001]
  • [Cites] Curr Opin Chem Biol. 2001 Oct;5(5):591-602 [11578935.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):41717-24 [11546792.001]
  • [Cites] Nat Biotechnol. 2002 Mar;20(3):301-5 [11875433.001]
  • [Cites] Nature. 2002 Apr 4;416(6880):560-4 [11932750.001]
  • [Cites] Exp Cell Res. 2002 Jun 10;276(2):194-200 [12027449.001]
  • [Cites] Cancer Cell. 2002 May;1(4):369-79 [12086851.001]
  • [Cites] Neoplasia. 2002 Sep-Oct;4(5):400-8 [12192598.001]
  • [Cites] Cell Cycle. 2002 May-Jun;1(3):162-8 [12429926.001]
  • [Cites] Anal Chem. 2002 Nov 1;74(21):5593-9 [12433093.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(7):2264-76 [12640112.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12207-13 [12519769.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2351-7 [12750249.001]
  • [Cites] Laryngoscope. 2003 Jun;113(6):936-9 [12782800.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3635-44 [12789272.001]
  • [Cites] Prog Cell Cycle Res. 2003;5:235-48 [14593718.001]
  • [Cites] Cell Cycle. 2004 Nov;3(11):1358-62 [15492512.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):758-66 [15705872.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5056-61 [15788536.001]
  • [Cites] Nat Cell Biol. 2005 May;7(5):493-500 [15834407.001]
  • [Cites] Cell Cycle. 2005 May;4(5):710-6 [15846104.001]
  • [Cites] J Biol Chem. 2005 Jul 8;280(27):25485-90 [15899889.001]
  • [Cites] EMBO J. 2005 Jul 6;24(13):2458-71 [15944736.001]
  • [Cites] Mol Cancer. 2005;4(1):25 [16033649.001]
  • [Cites] Oncogene. 2005 Oct 20;24(46):6970-5 [16007154.001]
  • [Cites] Int J Mol Med. 2005 Dec;16(6):1065-70 [16273287.001]
  • [Cites] Cell Cycle. 2005 Oct;4(10):1313-5 [16123597.001]
  • [Cites] Cell Cycle. 2005 Oct;4(10):1440-7 [16177572.001]
  • [Cites] Neuron. 2005 Dec 8;48(5):743-56 [16337913.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):37-45 [16327781.001]
  • [Cites] Cancer Cell. 2006 Jan;9(1):1-2 [16413463.001]
  • [Cites] Cancer Cell. 2006 Jan;9(1):45-56 [16413471.001]
  • [Cites] Methods Enzymol. 2005;405:82-115 [16413312.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):38-44 [16359856.001]
  • [Cites] Cell Cycle. 2006 Jun;5(12):1342-7 [16760655.001]
  • [Cites] Laryngoscope. 2006 Aug;116(8):1390-6 [16885742.001]
  • [Cites] Laryngoscope. 2006 Aug;116(8):1409-16 [16885745.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7870-9 [16912160.001]
  • [Cites] Development. 2006 Dec;133(23):4783-92 [17079275.001]
  • (PMID = 18769144.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / DE013561-08; United States / NIDCR NIH HHS / DE / R01 DE013561; United States / NIDCR NIH HHS / DE / R01 DE013561-08
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Protein Kinase Inhibitors; 0 / RNA, Small Interfering; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 1114-81-4 / Phosphothreonine; 17885-08-4 / Phosphoserine; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS280819; NLM/ PMC3069617
  •  go-up   go-down


79. Eng C: Anal cancer: current and future methodology. Cancer Invest; 2006 Aug-Sep;24(5):535-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer: current and future methodology.
  • Despite the small number of patients affected by carcinoma of the anal canal it remains one of the most challenging cancers to treat.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Clinical Trials as Topic. Fluorouracil / therapeutic use. HIV Infections / complications. Humans. Mitomycin / therapeutic use. Neoadjuvant Therapy. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm, Residual. Papillomavirus Infections / complications

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939964.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 64
  •  go-up   go-down


80. Schütz A, Härtig W, Wobus M, Grosche J, Wittekind Ch, Aust G: Expression of ADAM15 in lung carcinomas. Virchows Arch; 2005 Apr;446(4):421-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to analyze the expression of ADAM15 and its potential ligand, integrin alpha(v)beta3 (CD51/CD61), in lung carcinoma cell lines and tissues.
  • Most small cell lung carcinomas (SCLCs) and non-SCLC cell lines were ADAM15, alpha(v) and beta3 integrin mRNA positive.
  • Half of the cell lines expressed ADAM15, and three expressed the alpha(v)beta3 heterodimer at the cell surface as shown using flow cytometry.
  • Paraffin sections of pulmonary epithelial tumors, including SCLCs (n=26), squamous cell cancer (SCCs, n=27) and adenocarcinomas (ACs, n=17) were stained with antibodies to the ectosolic and cytosolic domain of ADAM15 and alpha(v)beta3 integrin complex.
  • In summary, lung carcinoma cell lines and tissues were frequently ADAM15 positive.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Integrin alphaVbeta3 / metabolism. Lung Neoplasms / metabolism. Membrane Proteins / metabolism. Metalloendopeptidases / metabolism
  • [MeSH-minor] ADAM Proteins. Aged. Cell Line, Tumor. Female. Flow Cytometry. Humans. Lung / cytology. Lung / metabolism. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):260-7 [8751559.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 18;235(2):437-42 [9199213.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1033-8 [10514384.001]
  • [Cites] J Cell Sci. 1999 Feb;112 ( Pt 4):579-87 [9914169.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):33683-9 [12091380.001]
  • [Cites] Differentiation. 1988;37(2):158-71 [2840315.001]
  • [Cites] Haematologica. 2002 Aug;87(8):836-45 [12161360.001]
  • [Cites] Curr Opin Cell Biol. 2003 Oct;15(5):598-606 [14519395.001]
  • [Cites] Pathol Res Pract. 1998;194(10):701-4 [9820866.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2062-9 [15026344.001]
  • [Cites] J Biol Chem. 1998 Oct 2;273(40):26236-47 [9748307.001]
  • [Cites] J Biol Chem. 2000 Nov 10;275(45):34922-30 [10944520.001]
  • [Cites] J Biol Chem. 1996 Mar 1;271(9):4593-6 [8617717.001]
  • [Cites] Thromb Haemost. 2003 Apr;89(4):622-31 [12669115.001]
  • [Cites] J Cell Biol. 1996 Sep;134(5):1323-32 [8794871.001]
  • [Cites] Cell. 1996 May 31;85(5):683-93 [8646777.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(16):5614-24 [12897135.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(2):127-47 [2424168.001]
  • [Cites] Mol Immunol. 1987 Jul;24(7):699-705 [3309626.001]
  • [Cites] Trends Cell Biol. 1994 Jul;4(7):256-61 [14731666.001]
  • [Cites] Eur Respir J. 1998 Feb;11(2):400-7 [9551745.001]
  • [Cites] Clin Exp Metastasis. 2002;19(8):717-25 [12553378.001]
  • [Cites] J Biol Chem. 2002 May 17;277(20):17804-10 [11882657.001]
  • [Cites] Neoplasia. 2002 May-Jun;4(3):191-4 [11988838.001]
  • [Cites] Oncol Res. 1993;5(10-11):441-51 [8054705.001]
  • [Cites] Pathobiology. 2004;71(4):185-92 [